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1. Soft tissue sarcomas  
 
Soft tissue sarcomas (STS) are rare malignant mesenchymal tumors, which occur in soft tissues 
of the body such as fat, deep skin tissues, muscles, blood vessels, and other connective tissues 
(Fig.1). They have a high diversity as the WHO categorizes more than 50 various subtypes 
based on their anatomical location, tissue of origin and biological potential [1]. Their rarity, 
STS account for 1% of all adult malignant tumors, and diversity within and across various 
subtypes classifies them among the more challenging malignant tumors. Each subtype 
represents unique and distinct clinical and biological features, which have significant impact 
on the prognosis and diagnosis of these malignant neoplasms as well as on their sensitivity 
towards chemotherapy. Moreover, the body location of STS is also variable making it even 




Figure1. Most common soft tissue sarcomas in the Netherlands [2]. The depicted incidence percentages 
for each subtype are calculated from the 2006-2011 soft tissue sarcoma patient cohort (≥18 years, n = 
3317) in the Netherlands.
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1.1 Limitations in clinical care of STS  
 
For patients with advanced STS who are not candidates for treatment approaches with a 
curative intent, systemic treatment with anti-tumor drugs remains the only option next to best 
supportive care. Concerning drug development, oncology has a higher failure in clinical trials 
compared to other disease areas and this holds true for drug development in advanced STS as 
well. There are multiple underlying reasons for this including suboptimal preclinical drug 
validations because of preclinical models that do not accurately represent the complexity of 
human cancers. Also tumor heterogeneity, even within a single STS subtype significantly 
impacts prognosis, diagnosis, and therapeutic responses of the patients. This brings major 
limitations and consecutive challenges for successful and effective treatment of these patients. 
The advent of molecular biology and emergence of advanced genetic approaches allows to get 
a better insight into the tumor biology of the diverse STS subtypes, and has -up to a certain 
extent- improved the accuracy of clinical care for some STS patients. Relevant molecular 
techniques include: fluorescent in situ hybridization (FISH), next-generation sequencing 
(NGS), gene (mRNA) expression analysis, miRNA expression profiling, karyotype analysis 
and polymerase chain reaction (PCR) [3]. For example, an improved understanding of the 
biology of gastrointestinal stromal tumors (GIST), a STS sub-entity that originates from 
interstitial cells of Cajal (ICC), revealed that the majority of these tumors are driven by gain-
of-function mutations in c-KIT or in PDGFR-α. The introduction of imatinib, a tyrosine kinase 
inhibitor that targets these mutants [5, 6], has dramatically improved the outcome for GIST 
patients. Initially patients faced only a 9 months overall survival (OS) which increased, 
because of imatinib, to 5 years [4] with a median progression-free survival of about 2 years 
with a response rate of approximately 50% [5]. Despite the revolutionary role of imatinib 
therapy in these patients, the vast majority develops resistance due to the acquisition of several 
resistance mechanisms [6]. Resistance mechanisms may be multi-factorial and display intra- 
and intertumoral heterogeneity emphasizing the importance of identifying and molecularly 
characterizing the GIST subpopulations to define effective therapeutic regimens for these 
patients. 
 
The chemotherapeutic drug pazopanib is a treatment option for patients with advanced non-
adipocytic STS after failure to prior chemotherapy. In general, tumor progression after 4 to 6 
months of pazopanib treatment is observed. However, it has been shown that the exact duration 
of pazopanib response varies remarkably between different histological STS subtypes as well 
as within the same tumor type [7]. Failure of pazopanib treatment in STS highlights the need 
to discover subsequent effective treatments for these patients. To this end, cell viability assays, 
using different experimental drugs, as well as genomic profiling experiments were conducted 
on cells and xenograft models generated from pazopanib resistant tumors. These analyses did 
show impaired tumor cell growth upon BEZ235 (Dactolisib, a PI3K inhibitor) and AZD2014 
(Vistusertib, a mTOR inhibitor) treatments inhibiting the mTOR/AKT pathway in refractory 
undifferentiated pleomorphic sarcoma. These drugs have been suggested as an alternative 
treatment option for patients who did not respond to pazopanib in clinical trials [8]. 




biology as well as systematically testing alternative therapeutic strategies in a rational fashion 
is imperative to make progress and develop better and more effective treatments.  
 
Another major hurdle in acquiring successful therapies for STS patients is the poor 
understanding of underlying mechanisms involved in tumorigenesis and tumor progression 
due to the lack of representative and reliable pre-clinical models. Malignant peripheral nerve 
sheath tumors (MPNST) are another example of a challenging malignancy. MPNST are highly 
aggressive STS with a high local recurrence rate as well as the propensity to metastasize and 
resistance to therapeutic interventions. About half of these tumors arise in the context of a pre-
existing benign counterpart, plexiform neurofibromas as they occur in neurofibromatosis type 
1 (NF1) patients [9]. Lack of knowledge of the underlying mechanisms of MPNST formation 
and metastasis in the NF1 setting is another deficiency in the field. A better understanding of 
MPNST biology and the molecular drivers of the malignant transformation from 
neurofibromas to MPNST is therefore needed to reveal new and effective treatment targets. 
Recent studies, using human cell line models and genetically engineered mouse models, have 
identified candidate genes and biochemical pathways that may be targeted for therapeutic 
purposes. However, as of yet none of these findings was translated into novel treatments for 
MPNST patients [10]. This might be due to crucial cross-species differences and biological 
variability that exist between the animal and human cell line models of MPNST on one hand, 
and the actual characteristics and behavior of these tumors in patients. Xenograft models only 
partly solve these problems (cross-species differences) as they usually simulate a single cancer 
stage and do not model early stages of tumor formation and progression. Apart from the above 
mentioned hurdles, tumor heterogeneity between different individuals should not be 
underestimated. In order to overcome these obstacles the generation of a reliable pre-clinical 
model that allows us to monitor the various stages of tumorigenesis and tumor progression is 
necessary. The analysis of the distinct cellular and molecular phenotypes of cells, going 
through distinct stages of tumor formation, may lead to the discovery of novel genes/pathways 
involved in carcinogenesis, the identification of reliable biomarkers for early diagnostic 
purposes and new therapeutic opportunities.  
 
1.2 Future directions to improve STS patient’s outcome 
 
Although great strides have been made in improving the clinical care for STS patients, a lot is 
still unknown about this heterogeneous group of tumors, which makes it challenging to 
develop effective therapies. The increasingly advanced and sensitive molecular techniques 
have already promoted our understanding of STS etiology and biology and bear great promise 
for the future. These developments will ultimately lead to novel and more effective ways of 
diagnosing and treating STS patients.  
We owe it to the patients who suffer from rare STS to translate laboratory findings to the clinic 
and patients as quickly as possible. International collaboration is in this respect extremely 
important, sharing resources like patient samples and unpublished experimental and clinical 
data on a world-wide scale. This can only happen if all involved parties cooperate including 




governments and patients. Only focus, hard work and setting aside personal interests will 
enable us to make progress for the benefit of the patient.  
 
2. MicroRNAs  
 
MicroRNAs (miRNAs) are involved in the pathobiology of many diseases. An improved 
understanding of their exact role in STS may yield the identification of specific miRNAs, 
which could serve as a prognostic or predictive biomarker or as a target for treatment. In 1993, 
the first small non-coding RNA, lin-4, was discovered through a forward genetic screen in the 
nematode Caenorhabditis elegans [11]. The negative regulatory role of this small RNA 
molecule on the expression/function of the protein coding lin-14 was further established in the 
same year [12]. The field got a major impetus with the discovery of another small RNA 
involved in developmental timing in nematodes, let-7. In contrast to lin-4, let-7 was 
phylogenetically highly conserved and could be detected in variety of animals including 
humans [13]. It soon became clear these small (18-25 nucleotides) RNA molecules represented 
a novel class of endogenous, evolutionarily conserved small RNA molecules, microRNAs, that 
negatively regulate gene expression at a post-transcriptional level [14]. They play pivotal roles 
in the regulation of fundamental cellular and physiological processes and are closely involved 
in the pathobiology of many disorders including cancer. Advances in next-generation 
sequencing methodologies [15] followed by computational/bioinformatics analyses have 
greatly facilitated research into the regulatory role of miRNAs and the subsequent effects on 
their mRNA targets [16]. In general miRNAs negatively regulate gene expression by binding, 
in the context of the RNA-induced silencing complex, to the 3’ untranslated region (3’ UTR) 
of target mRNAs. In some cases, however, the 5’UTR or open reading frame (ORF) are 
reported as binding site for miRNAs [17, 18]. The miRNA binding causes mRNA 
destabilization/degradation and/or inhibition of mRNA translation [19, 20].  
 
a. MiRNAs biogenesis canonical and non-canonical 
pathways 
 
In mammalian cells mature miRNAs can be generated from endogenous transcripts that fold 
into hairpin structures by canonical and non-canonical processes. The majority of miRNAs are 




Canonical miRNA biogenesis starts with the transcription of a long precursor molecule in the 
nucleus called primary-miRNA (pri-miRNA) (Fig.2). One (monocistronic) or multiple 
(polycistronic) hairpin loop structures are embedded within the pri-miRNAs, which have 




for RNA binding and processing proteins. Next, within the nucleus, the microprocessor 
complex, which includes an RNA-binding protein (DGCR8) and a nuclear RNase III enzyme 
(DROSHA) processes the pri-miRNA. The transcript is cleaved at the base of the hairpin loop, 
which leaves behind a 2-nt 3’ overhang  [21]. The resulting  ∼70-nt hairpin-like secondary 
transcript is known as the precursor miRNA (pre-miRNA). Pre-miRNAs are then translocated 
to the cytoplasm mediated by Exportin-5 and Ran-GTP [22]. The terminal loop of the pre-
miRNAs is subsequently removed by another RNase III endonuclease Dicer releasing a ∼22-
nt double stranded RNA (dsRNA) [23]. Dicer binding to the pre-miRNAs is assisted by the 
help of TRBP, which is an RNA binding protein pivotal for increasing Dicer binding affinity 
and its cleavage accuracy [24, 25]. The dsRNA is bound by Argonaute2 (Ago2) protein, which 
ultimately forms part of the RNA-induced silencing complex (RISC) and has crucial roles in 
unwinding of the duplex and selecting the mature miRNA strand [26]. The duplex contains 
two partially complementary miRNAs (miRNA/miRNA*) of which in most cases the 
passenger or star(*) strand gets degraded. With the help of Ago2 and several other proteins, 
the mature miRNA strand is loaded into the RISC complex and guided towards specific 
binding sites on target messenger RNAs (mRNAs). Ago2 and glycine-tryptophan 182 
(GW182) are among the key components for the assembly and function of the RISC complex, 
in which the GW182 acts as the downstream effector in repression. GW182 functions as a 
flexible bridge to make the interactions between RISC and other downstream proteins in the 
RISC complex. Depending on the complementarity region between the (seed) region of the 
mature miRNA and targeted mRNA, translational inhibition and/or mRNA 
degradation/destabilization will take place [27]. MiRNAs can act as potential translational 
repressors by partially pairing with the 3’, 5’ UTRs or coding sequences without any impact 






Figure2. Canonical miRNA biogenesis. The pri-miRNA is generated by the activity of RNA polymerase 
II. This long transcript is then processed by DROSHA-DGCR8 resulting in the production of the pre-
miRNA in the nucleus. This ∼70-nt hairpin-like structure is then transported to the cytoplasm with the 
help of  Exportin-5 and Ran-GTP. Dicer and TRBP are involved in a second RNA processing step and 
consequently the production of a double stranded RNA molecule containing the mature miRNA and a 
passenger strand which may be degraded or also function as mature miRNA. The double stranded RNA 
and eventually the mature miRNA is attracted to the Argonaute proteins and eventually incorporated into 






Some miRNAs are formed by a non-canonical pathway, independent of DROSHA/DGCR8 
activity [29]. This has been demonstrated by the deletion of DROSHA and DGCR8, encoding 
the two proteins that constitute the microprocessor complex, which resulted in a complete loss 
of canonical miRNAs. However, no impact was observed on the biogenesis of non-canonical 
miRNAs [30, 31]. So called miRtrons are among the first discovered non-canonical generated 
miRNAs, for which the presence of the cytoplasmic Dicer is still indispensable [31]. Their 
generation is initiated with the transcription of short introns of protein-coding genes, which 
are subsequently spliced out of the primary transcript by the spliceosome.  The short intron 
sequences that contain a miRNA fold into characteristic hairpin-like structures. Most 
mammalian hairpins that form this way contain a relatively high GC content that increases the 
stability of these structures [32]. The resulting short-sized hairpins (pre-miRNAs) are next 
delivered to the cytoplasm by Exportin-5 in order to be cleaved by Dicer. In the miRtron 
pathway (non-canonical miRNA biogenesis pathway) the microprocessor process is replaced 
by the splicing activity, and further on, upon nuclear export merges with the canonical 
pathway.  
 
Analysis of the genomic loci within the non-mirtronic regions have illustrated signs of Dicer-
dependent/microprocessor-independent reads. MiR-320 and miR-484 are among these groups 
and their transcripts have elucidated the potential in forming the hairpin structures [33, 34].  
 
b. MiRNAs functions 
 
A single miRNA is capable of targeting multiple, perhaps hundreds of mRNAs, thereby 
affecting their expression. At the same time a single mRNA may be targeted by several 
miRNAs. The picture that arises is that of a complex miRNA-mediated regulatory network 
that governs biochemical processes within cells and tissues that directly affect physiological 
and pathological processes. As these regulatory events must be carefully orchestrated both 
spatially and temporally miRNA activity is probably highly regulated. Binding of miRNAs in 
the context of RISC to target mRNA causes mRNA degradation and/or translation inhibition 
[35, 36]. MiRNA-mediated translational repression/silencing can occur by distinct processes: 
(i) deadenylation and mRNA degradation, (ii) 5’-decapping, and (iii) ribosome detachment 
[37]. These post-transcriptional silencing processes are all initiated by the association of 
miRNAs with the RISC components and the degree of sequence complementarity between the 
miRNA and the target mRNA determines the type of activity. MRNA 
destabilization/degradation takes place if there is a high level of complementarity. However, 
the presence of several mismatches within the miRNA/mRNA duplex facilitates translational 
repression, which is the most common event taking place in mammals [37, 38]. MiRNAs can 
act as potential translational repressors by partially pairing with the 3’, 5’ UTRs or coding 
sequences without any impact on the structural integrity of the targeted mRNAs [39]. The net 





c. MiRNAs in cancer 
  
In 2001 reports described the presence of highly conserved small non-coding RNA molecules 
(miRNAs) in multiple eukaryotic organisms and mammalian species [40, 41]. Over the past 
decade it became clear that miRNAs fulfil a crucial role in cancer initiation, progression and 
metastasis [42-44]. In the context of cancer certain miRNA may be considered as oncogenes 
or tumour suppressors. A consistent finding in cancer is the tumor-specific dysregulation of 
miRNA expression with most miRNAs found to be downregulated in cancer [45]. The exact 
molecular reasons for aberrant miRNA expression are not always known and may include 
epigenetic silencing i.e. hyper-methylation of the promoter regions of miRNA genes or histone 
methylation [46-49]. Alternatively, defects within the miRNA biogenesis pathways can also 
modulate miRNA expression levels. Mutations within genes Dicer [50] or Exportin-5 [51], 
result in the accumulation of pri-miRNAs and the depletion of mature miRNAs [52]. The 
presence of single-nucleotide polymorphisms (SNPs) in both miRNA genes and/or their 
mRNA targets may increase the complexity. SNPs have been described that impair pri-miRNA 
processing [53] and SNPs within miRNA binding sites in mRNA may affect miRNA mediated 
regulation [54].   
 
The aberrant miRNA expression profiles can be quantitatively determined in tumor samples 
using different methodologies and platforms including microarrays, RT-PCR and next 
generation sequencing approaches [55-58]. These profiling studies – often comparing cancer 
with relevant or adjacent normal tissues – have led to the identification and further 
characterization of miRNAs that initiate and/or contribute to the process of tumorigenesis in a 
variety of cancers [42, 59]. The expression profiles have also been instrumental for diagnostic 
purposes but have also been exploited for prognostic and predictive biomarker purposes [57, 
60-62]. Currently much attention is being given to minimally-invasive liquid biopsies (whole 
blood, serum, plasma and urine) in which cancer–related miRNAs can be found to circulate 
and used as biomarker [63-65]. As miRNAs are small, often bound to proteins or associated 
with vesicular structures such as exosomes in the circulation they are relatively resistant to 
degradation and therefore suited as biomarker. Although many researchers report on miRNA 
biomarkers in different cancers, very few are actually used in the clinic. This may be due to 
the poor reproducibility of many studies because of limited sample numbers, sample 
heterogeneity, biased sample selection, poorly annotated samples, the use of different detection 
platforms and the use of poorly standardized protocols and normalization procedures [42, 66]. 
For many cancers the current literature implies the existence of relevant miRNA-based 
biomarkers, however, well-devised validation studies are needed to identify the most reliable 
and robust miRNA biomarkers.  
 
In recent years interest arose to exploit miRNAs for their therapeutic potential in cancer. For 
example, a miRNA that is overexpressed in cancer may be inhibited through antisense 
miRNAs (antimirs) or alternatively, the expression of a miRNA that is downregulated may be 
restored. Therefore, miRNA-based treatment strategies can be conducted in two ways: miRNA 




MiRNA mimics are chemically synthesized double-stranded RNAs that harbor the same 
sequence as the corresponding miRNA and functionally restore the loss of its expression. By 
contrast, antimiR inhibitors are single-stranded chemically modified antisense 
oligonucleotides which are designed to bind to the complementary sequence of the over-
expressed miRNA in order to block its function. MiR-122, miR-103/107, miR-155, miR-29, 
miR-16 and miR-34 are among the most common tumor suppressor and oncogenic miRNAs 
that are currently being used as therapeutic molecules in clinical trials [42, 67]. Similar to other 
forms of systemic therapy adverse effects may occur of which the nature and severity may 
vary depending on the miRNA that is modulated. Of note, a phase I clinical trial involving 
liposomal miR-34a (MRX34, Mirna Therapeutics) was prematurely terminated due to multiple 
immune-related severe adverse events [68].  
 
Despite the potential of miRNAs for cancer therapy, RNA-based therapeutic approaches 
(mimics and antimiRs) encounter considerable challenges. One of the major barriers in 
miRNA-based therapeutic delivery is the risk of RNA-degradation in the blood or endocytic 
compartment by RNases before reaching the target or target cells. To make miRNA-based 
therapeutic less prone to degradation, several nucleotide modifications in the RNA backbone 
have been incorporated: replacement of the phosphodiester group with a phosphorothioate (PS) 
linkage, introduction of an O-methyl or 2-methoxyethyl group, and the use of locked nucleic 
acids (LNAs) [69]. PS oligonucleotides exhibit dramatic increase in their half-life. However, 
chemical modifications may result in the production of toxic molecules as a result degradation 
processes that may lead to off-target gene silencing [70]. In addition to the biological stability 
issues, another concern when using these miRNA-based therapeutic molecules is the target-
specific delivery and efficiency of cellular uptake [71]. Non-viral and viral strategies for 
delivery have been designed although the use of viral vectors in the clinic is still not widely 
encouraged due to the safety issues [72]. Non-viral carriers are safer, biodegradable and non-
immunogenic delivery particles, which can be made up of synthetic polymers or lipids [71]. 
Encapsulating the candidate small-RNAs therapeutics using EnGenelC Delivery Vehicles 
(EDV) nanocells, poly (ethylene glycol) (PEG) and N-acetyl-D-galactosamine are among the 
most common delivery systems being used and evaluated in clinical trials [73-75]. Other 
delivery particles such as dendrimers, neutral lipid emulsions, chitosan, cyclodextrin, poly 
(lactic-co-glycolide) (PLGA), and synthetic polyethylenimine (PEI) are still mostly used in 
pre-clinical studies due to their dose-limiting toxicity, low efficiency in delivering to the tumor 
cells, and the low rate of loading small-RNA molecules in these particles [76-80]. A faulty or 
non-targeted delivery may lead to off-target and adverse effects through the modulation of 
gene expression in non-cancerous tissues or cause immune responses. In order to increase 
target-specificity, two main approaches are proposed: 1) utilizing synthetic oligonucleotide 
nanoparticles that are coated with antibodies specific for binding to the desired tumor cells, 
and/or 2) direct injection of these nucleotides into the tumor itself (examples; sarcomas and 
brain tumors) instead of a systemic administration [70, 71]. 
 
Despite all challenges, advanced discoveries on miRNAs-mediated regulatory processes have 
led to a better understanding of the underlying biological mechanisms operational in 
carcinogenesis [42, 66, 81, 82]. The potential of miRNAs in simultaneously regulating several 




circulation make them suitable biomarker and therapeutic candidates for many disorders. 
Although the application of miRNAs in the clinic, either as biomarker or for therapeutic 
purposes, is still in its infancy, the strong involvement and determining roles of miRNAs in 
different aspects of carcinogenesis hold great promise to make an impact on patient care in the 
near future.  
 
3. Thesis outline 
 
In order to improve the clinical outcome of patients with STS, a better understanding of the 
molecular mechanisms involved in carcinogenesis is crucial. In Chapter 2, we studied the 
potential therapeutic role of targeting BRD4, EZH2 and TOP2A in a STS sub-group called 
MPNSTs.  
 
De-regulated miRNAs, commonly observed in cancers, are known to contribute to 
tumorigenesis and cancer progression. Their use as diagnostic, prognostic and predictive 
biomarker as well as their therapeutic potential is widely studied. In Chapter 3, the 
involvement of miRNAs in key cancer-related processes in NF1-derived MPNST was 
investigated.  
 
An overview of the aberrant expression and association with clinicopathological parameters 
of non-coding RNAs, particularly miRNAs, in GIST is provided in Chapter 4. GIST patients 
are effectively treated with the tyrosine kinase inhibitor imatinib but ultimately develop drug 
resistance causing tumor progression. In Chapter 5 miRNAs and genes were identified 
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Malignant peripheral nerve sheath tumors (MPNST) are rare, highly aggressive sarcomas that 
can occur spontaneously or from pre-existing plexiform neurofibromas in neurofibromatosis 
type1 (NF1) patients. MPNSTs have high local recurrence rates, metastasize easily, are 
generally resistant to therapeutic intervention and frequently fatal for the patient. Novel 
targeted therapeutic strategies are urgently needed. Standard treatment for patients presenting 
with advanced disease is doxorubicin based chemotherapy which inhibits the actions of the 
enzyme topoisomerase IIα (TOP2A). Recent molecular studies using murine models and cell 
lines identified the bromodomain containing protein 4 (BRD4) and enhancer of zeste 
homolog 2 (EZH2) as novel targets for MPNST treatment. We investigated the expression 
and potential use of BRD4, EZH2 and TOP2A as therapeutic targets in human NF1-derived 
MPNSTs. The transcript levels of BRD4, EZH2 and TOP2A were determined in paired 
formalin-fixed paraffin-embedded (FFPE) neurofibroma/MPNST samples derived from the 
same NF1 patient and in a set of plexiform neurofibromas, atypical neurofibromas and 
MPNST. We further examined the effect on cell viability of genetic or pharmacological 
inhibition of BRD4, EZH2 and TOP2A in an MPNST cell line panel. Our results indicated that 
in MPNST samples BRD4 mRNA levels were not upregulated and that MPNST cell lines were 
relatively insensitive to the bromodomain inhibitor JQ1. We corroborated that EZH2 mRNA 
expression is increased in MPNST but failed to confirm its reported pivotal role in MPNST 
pathogenesis as EZH2 knockdown by siRNA did not interfere with cellular proliferation and 
viability. Finally, the relation between TOP2A levels and sensitivity for doxorubicin was 
examined, confirming reports that TOP2A mRNA levels were overexpressed in MPNST and 
showing that MPNST cell lines exhibited relatively high TOP2A protein levels and sensitivity 
to doxorubicin. We tentatively conclude that the potential for effective therapeutic intervention 
in MPNST by targeting BRD4, EZH2 and TOP2A individually, may be limited. Clinical 
studies are necessary to ultimately prove the relevance of BRD4 and EZH2 inhibition as novel 





Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder which has a de novo 
incidence of one in 3000 individuals (1-3). This genetic disorder is caused by defects in the 
NF1 gene located on chromosome 17q11.2. The NF1 gene encodes a tumor suppressor called 
neurofibromin 1, which through its GTPase-activating protein (GAP) domain negatively 
regulates Ras signaling keeping cell proliferation in check. Inherited or sporadic mutations of 
NF1 and the partial inactivation of neurofibromin, lead to an increased risk of developing 
various tumors. Almost all NF1 patients develop cutaneous neurofibromas and in many 
patients plexiform neurofibromas cause additional morbidity. All tumors exhibit biallelic 
inactivation of the NF1 gene and consequently activated signaling through the Ras pathway 
driving cancer formation (1, 4). Plexiform neurofibromas may transform into malignant 
peripheral nerve sheath tumors (MPNST), the most common malignancy occuring in NF1 
patients, at an incidence of 2% and a lifetime risk of 8-13% (5). MPNSTs are classified in the 
group of the soft tissue sarcomas (STS) and comprise approximately 5-10% of all STS. 
MPNST are a class of highly aggressive and clinically challenging sarcomas. High local 
recurrence rates, early metastasis and resistance to chemotherapy are common clinical 
phenotypes in this cancer. When metastasized, patients face a poor prognosis with only a 
limited number of systemic chemotherapeutic agents available (6, 7).  Of these, doxorubicin is 
probably the most active one, targeting - through intercalation into the DNA - the activity of 
the enzym topoisomerase IIα (TOP2A) (8). Transcriptome data analyses have shown that 
TOP2A was among the most upregulated genes in MPNSTs when compared to benign 
neurofibromas (9, 10). However, despite the high expression of TOP2A, advanced MPNST 
patients do not respond well to doxorubicin given a 2 year overall survival rate of 
approximately 20%, which is roughly equivalent to the outcome of patients with metastatic 
STS other than MPNST (7). This poor outcome clearly underscores the need to get better 
insight into the exact relationship between TOP2A expression and doxorubicin sensitivity in 
MPNST and the necessity to reveal new leads for treatment. 
 
A better understanding of the pathobiology of MPNST may lead to the identification of novel 
treatment targets. Recently, Patel et al. reported the upregulation of Brd4 mRNA and protein  
levels in a newly developed murine MPNST model (11, 12) based on transplantation of Nf1-/-
,P53-/- skin-derived precursor cells into nerves of athymic nude mice (13). Further 
investigations inferred a critical role for Brd4 in MPNST pathogenesis as inhibition by 
shRNAs or by JQ1, a small molecule BET (bromodomain and extraterminal domain) inhibitor, 
severely impaired in vitro growth and in vivo tumorigenesis (13). It was demonstrated that 
inhibition of Brd4 induced expression of the pro-apoptotic molecule Bim leading to apoptosis 
in MPNST cells. The BET subfamily of bromodomain proteins to which BRD4 belongs has a 
role in regulating transcription by RNA polymerase II. The best studied member BRD4 recruits 
transcriptional regulatory complexes to acetylated chromatin and modulates transcriptional 
elongation of essential genes involved in cell cycle and apoptosis (14). In addition, also 
enhancer of zeste homolog 2 (EZH2) was found upregulated in MPNST compared to 
neurofibroma and normal nerves (15). EZH2 is a core element of the polycomb repressive 
complex 2 (PRC2) a well-known epigenetic modulator of gene expression (16) and is 
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frequently found overexpressed in malignancies or mutated in lymphomas (17). EZH2 
involvement in MPNST pathogenesis was demonstrated by the transient EZH2 knockdown 
using si/shRNA or EZH2 inhibition by 3-deazaneplanocin A causing cell cycle arrest and 
apoptosis in MPNST cells (15, 18). Evidence is provided for the existence of a novel signaling 
pathway in MPNST that mediates the effects of EZH2 via miR-30a/30d to karoypherin 
(importin) beta 1 (KPNB1) (15, 18).  Both EZH2 and BRD4 can be targeted by selective and 
potent small molecule inhibitors (19, 20) that are currently being evaluated in clinical trials 
making them appealing targets for the treatment of MPNST. 
 
To further investigate the potential role as treatment targets of the above-mentioned proteins, 
we investigated the expression level of the target genes in FFPE and fresh frozen sample sets 
of plexiform neurofibromas and MPNSTs as well as neurofibroma and MPNST cell lines in 
order to validate the obtained results from the previous studies. 
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Materials and methods 
 
Patients and samples  
 
From the Erasmus MC patient files, nine neurofibroma type 1 patients were selected of which 
resected plexiform neurofibroma material was present and who developed MPNST. Archival 
formalin-fixed paraffin-embedded (FFPE) tumor samples of both plexiform neurofibroma and 
MPNST from the same patient (paired samples) were recovered from the Erasmus MC tissue 
bank. Fresh frozen samples from plexiform neurofibroma (n=11), atypical neurofibroma (n=4) 
and MPNST (n=7) were also obtained from the Erasmus MC tissue bank. The FFPE and fresh 
frozen sample sets do not overlap and were derived from distinct patients. All patients and 
tumor characteristics are listed in Table 1. For the histopathological diagnosis of MPNST, 
atypical neurofibroma and plexiform neurofibroma criteria were used as described before (21, 
22) in accordance with the 2016 WHO classification of Tumours of the Central Nervous 
System (23). 
 
In short, for the diagnosis of MPNST we used morphological criteria. Immunostaining for 
S100 was used for identification of a Schwann cell component in the tumors. Atypical 
neurofibroma was defined by the presence of mitotic figures, and/or cytological atypia, and/or 
increased cellularity. The combination of all three features, however, defined low grade 
MPNST. Plexiform neurofibroma involved multiple nerve fascicles and lacked the above 
mentioned atypical features. Prior to our research the Daily Board of the Medical Ethics 
Committee Erasmus MC of Rotterdam, The Netherlands, reviewed the research proposal. As 
a result of this review, the Committee decided that the rules laid down in the Medical Research 
Involving Human Subjects Act do not apply to this research (MEC-2016-213).
27 
 
Table 1. Patient and tumor characteristics. 
   Paired FFPE tumor samples (n = 9 pairs) 
Gender  
Male 6 (66.7%) 
Female  3 (33.3%) 
Age at biopsy/resection NF (years)  
Median (range) 28 (5-63) 
Age at biopsy/resection MPNST (years)  
Median (range) 27 (14-70) 
Plexiform neurofibroma 
Head and Neck 1 (11.1%) 
Extremities  3 (33.3%) 
Trunk 5 (55.6%) 
MPNST  
Head and Neck 1 (11.1%) 
Extremities  4 (44.4%) 
Trunk 4 (44.4%) 
Fresh frozen tumor samples 
Plexiform neurofibroma (n = 7)  
Gender  
Male 4 (57.1%) 
Female  3 (42.9%) 
Age at biopsy/resection (years)  
Median (range) 29 (10-63) 
Location  
Head and Neck 1 (14.3%) 
Extremities  4 (57.1%) 
Trunk 2 (28.6%) 
Atypical neurofibromas (n = 4)  
Gender   
Male 2 (50%) 
Female  2 (50%) 
Age at biopsy/resection (years)  
Median (range) 25.5 (15-43) 
Location  
Head and Neck - 
Extremities  4 (100%) 
Trunk - 
MNST (n = 11)  
Gender   
Male 5 (45.5%) 
Female  6 (54.5%) 
Age at biopsy/resection (years)  
Median (range) 36 (12-76) 
Location  
Head and Neck 3 (27.3%) 
Extremities  3 (27.3%) 
Trunk 5 (45.4%) 
 





Human MPNST cell lines ST88-14, 90-8TL, T265 (NF1-associated MPNST) and STS26T 
(sporadic MPNST) were kindly provided by Dr. Eduard Serra (Institute of Predictive and 
Personalized Medicine of Cancer/IMPPC, Barcelona, Spain). sNF96.2 and HS53.T were 
obtained from the ATCC and derived from an NF1-associated MPNST and a cutaneous, NF1-
derived, neurofibroma, respectively. Human embryonic kidney (HEK) 293T cells were a kind 
gift from the department of Genetics, Erasmus MC, Rotterdam, the Netherlands). All cell lines 
were cultured in DMEM (Gibco Life Technologies) supplemented with 10% fetal bovine 
serum, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37 °C in a humidified 5% CO2 
atmosphere. All cell lines were regulary monitored for mycoplasma infection and were 
subjected to authentication by performing a short tandem repeat (STR) DNA analyses and 
matched, when available, with STR databases. The absence of SUZ12 protein expression in 
ST88-14 and 90-8TL as reported by de Raedt et al. (24) was confirmed by Western blotting 
(S1 Fig). Similarly, the presence or absence of detectable NF1 protein in the various cell lines 




Total RNA was isolated from cell line pellets and fresh frozen tissues using RNAbee (Tel test 
Inc., Friendswood, Texas, USA) according to the manufacturer’s instructions. RNA from 
FFPE tumor samples (5-6 20 µm sections) was isolated using the RecoverAllTM total nucleic 
acid isolation kit (Ambion/Life Technologies). RNA quality and quantity were checked using 




cDNA was synthesized from 250 ng of total RNA using TaqMan® Reverse Transcription 
Reagents (ThermoFisher Scientific).  The mRNA expression levels of target genes and 
housekeepers were determined by real time PCR using TaqMan® Universal PCR Master Mix 
and specific Assay-On-Demand products (ThermoFisher Scientific/Applied Biosystems) 
using an ABI 7500 Real-Time PCR machine. The following assays were used EZH2 
(Hs01016789_m1), TOP2A(Hs01032137_m1), BRD4(Hs04188087_m1). Expression of 
EZH2, TOP2A and BRD4 were normalized using PPIA (Pedersen et al, 2014) 
(Hs99999904_m1) using the comparative CT method (25). Each tumor or cell line RNA sample 
was measured in duplicate after which the data were analyzed using SDS software (Applied 
Biosystems). Statistical significance (p<0.05) was determined on the normalized expression 





Protein lysates, SDS-PAGE and Western blotting 
 
Total protein was extracted from cells using lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM 
NaCl, 10% glycerol, 1% NP-40, 0.5% Na-deoxycholate, 1 mM Na3VO4, 20 mM NaF, 1 mM 
Pefabloc) supplemented with a cocktail of protease inhibitors. Protein concentration was 
quantified using a Bradford assay (Bio-Rad, Veenendaal, The Netherlands).  Equal amounts 
of total protein (15 – 20 μg/lane) were subjected to SDS-PAGE and subsequently transferred 
to a PVDF membrane by electroblotting. Remaining protein binding sites of the membrane 
were blocked in PBS, 0.05% Tween 20 (PBS/Tween) containing 5% non-fat dried milk. 
Primary antibody incubations were carried out in the same buffer with the following primary 
antibodies: mouse monoclonal anti-EZH2 (1:1000, NCL-L-EZH2, Leica Microsystems;), 
rabbit monoclonal anti-SUZ12 (1:1000, D39F6, Cell Signaling Technology), rabbit polyclonal 
anti-BRD4 (1:10000, A301-985A100, Bethyl Laboratories, Inc), rabbit monoclonal anti-
TOP2A (1:1000, D10G9, Cell Signaling Technology), rabbit monoclonal anti-NF1 (1:1000, 
D7R7D, Cell Signaling Technology), rat monoclonal anti-tubulin (1: 4000, YL1/2, Abcam) 
and mouse monoclonal anti-β-actin (1:10000, A5441, Sigma-Aldrich). HRP conjugated goat-
anti-rabbit, goat-anti-mouse and goat-anti-rat were used as secondary antibodies. Enhanced 
chemiluminiscence (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific, 
Rockford, IL, USA) was used to visualise the signal in a ChemiDoc MP Imager (Bio-Rad, 
Veenendaal, The Netherlands). Protein expression was quantitated using ImageJ, a public 
domain Java-based image processing program (26). Each Western blot was replicated at least 
three times, depicted are representative blots.  
 
In vitro cytotoxicity assay 
 
In vitro cytotoxicity of the BET inhibitor JQ1 (BioVision Inc, Milpitas, CA, USA), and the 
anthracycline doxorubicin (Pharmachemie, Haarlem, The Netherlands) were determined by a 
sulforhodamine B (SRB) assay essentially as described by Keepers et al. (27). In brief, on day 
0 cells were plated in 96-well flat bottom microtiter plates. On day 1 a ten-step, two-fold 
dilution series was prepared and added to the cells resulting in a highest concentration of 2500 
nM for JQ1 and 500 ng/ml for doxorubicin. Every dilution was assayed in quadruplicate. After 
48 -72 hours the assay was terminated, the cells fixed with 10% trichloroacetic acid in PBS for 
1 h at 4°C. After at least four washes with tap water the cells remaining in the wells were 
stained with 0.4% SRB in 1% acetic acid for at least 15 min at RT. Subsequently the unbound 
stain was removed by 4 washes in 1% acetic acid. Plates were air-dried and bound stain was 
dissolved in 150 μl of 10 mM Tris-base. Staining was quantified by measuring the absorbance 
at 540 nm in a spectrophotometer. Concentration-response curves were generated and IC50 






EZH2 siRNA mediated knockdown 
 
Twentyfour hours prior to transfection the 90-8TL and T265 cell lines were plated in a 24-well 
plate in duplicate at such a concentration that the next day the wells reach 70-80% confluency. 
Cells were transfected with either a EZH2-specific siRNA (Qiagen, FlexiTube siRNA 
SI02665166) or a negative control scrambled siRNA (Qiagen, SI03650325) at a concentration 
of 50 nM using the DharmaFECT1 transfection reagent (Dharmacon/Thermo Scientific) as 
recommended by the manufacturer. Twentyfour hours post-transfection the medium was 
replaced with standard culture medium and cell density as a measure for proliferation was 





Human BRD4 mRNA levels are not increased in 
MPNST compared to neurofibromas 
 
In the search for targetable alterations in MPNST Patel et al. reported a potential pathogenic 
role of a BET bromodomain family member (Brd4) in an MPNST mouse model. Inhibition of 
Brd4, which was found highly upregulated in MPNST, induced increased expression of the 
pro-apoptotic molecule Bim inducing apoptosis in MPNST cells and tumor shrinkage (13). We 
examined BRD4 mRNA expression by qRT-PCR in a series of nine paired human MPNST 
and plexiform neurofibroma FFPE samples, each pair derived from the same patient (Fig 1A). 
To rule out that degradation of the total RNA isolated from the archival samples impairs 
accurate quantitation we also determined BRD4 mRNA levels in a set of fresh frozen plexiform 
neurofibromas (n=7), atypical neurofibromas (n=4) and MPNST (n=11) (Fig 1B). Both in the 
neurofibroma-MPNST pairs as well as in the fresh frozen samples we did not detect BRD4 
overexpression in the MPNST samples (Figs 1A,B). The paired sample analyses indicated 
significantly higher BRD4 mRNA levels in 6 of the neurofibromas compared to their 
corresponding MPNST whereas in most fresh frozen samples there was no significant 
difference in BRD4 mRNA levels between (atypical) plexiform neurofibromas and MPNSTs. 
It must be noted, however, that mRNA levels may not be indicative for protein levels as in 
most MPNST cell lines BRD4 mRNA levels were similar but BRD4 protein levels varied 
considerable (cf. Figs 1C and 1D). To further investigate whether BRD4 can serve as a target 
for treatment we determined the sensitivity of our cell line panel consisting of a neurofibroma 
and 5 MPNST cell lines, to the BET bromodomain inhibitor JQ1 (Fig 2A). In an in vitro 
cytotoxicity assay the cell lines were exposed to increasing concentrations of JQ1 for 72 hours. 
Most MPNST cell lines did not display a clearly increased sensitivity to JQ1 compared to the 
neurofibroma cell line. The MPNST cell lines sNF96.2, T265 and 90-8TL expressed 
approximately equal levels of BRD4 protein and displayed similar sensitivity to JQ1 (Fig 2B). 
ST88-14 another NF1-derived MPNST cell line expressed relatively low BRD4 protein levels 
and was accordingly found less sensitive to JQ1. In contrast the sporadic MPNST cell line 
STS26T harbors high levels of BRD4 protein but is relatively insensitive to JQ1. For these cell 



































































































































































































































































































































































































































































































































































Fig 2. Sensitivity of neurofibroma and MPNST cell lines to the BET bromodomain inhibitor JQ1. 
(A) An in vitro cytotoxicity assay (SRB assay) was used to determine IC50 values (nM) for the BET 
bromodomain inhibitor JQ1 of neurofibroma and MPNST cell lines after a 72h exposure to the drug. 
Graphs show cell viability as a function of JQ1 concentration.  
Depicted is the average viability (n=4) of a representative experiment. (B) Listing of calculated IC50 values 
and correlation plot, with BRD4 protein expression levels on the Y-axis and IC50 values for JQ1 on the X-
axis. Pearson correlation coefficient is depicted in the graph. 
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EZH2 levels are increased in MPNST compared to 
neurofibromas but do not affect cellular proliferation. 
 
Nuclear EZH2 levels were reported to be induced in MPNST compared to neurofibromas and 
normal nerves as measured by immunohistochemistry (15). Our observations support these 
results as the EZH2 mRNA levels were significantly increased in the MPNST samples from 6 
out of 9 plexiform neurofibroma/MPNST pairs (Fig 3A). Also in RNA isolated from fresh 
frozen neurofibroma and MPNST samples EZH2 mRNA levels appeared on average to be 8-
fold higher in MPNST than in (atypical) plexiform neurofibromas (Fig 3B). Similarly, all the 
MPNST cell lines displayed relatively high EZH2 mRNA levels compared to the neurofibroma 
cell line (Fig 3C). At a protein level, as judged by Western blot, EZH2 also seems more highly 
expressed in the MPNST cell lines although it is clear that protein expression and mRNA levels 
do not always perfectly match (Fig 3D). Next, we investigated whether EZH2 inhibition exerts 
an anti-proliferation activity as was previously reported (15). Both T265 and 90-8TL MPNST 
cells were transiently transfected with an EZH2 siRNA and a scrambled siRNA control for 
comparison. EZH2 protein levels were significantly reduced by the EZH2 siRNA treatment at 
48 – 72 h after transfection (Fig 4A).  However, despite the clearly decreased EZH2 levels no 











































































































































































































































































































































































































































































































































































Fig 4. siRNA mediated knockdown of EZH2 and its effect on cell proliferation. (A) Western blot 
showing the effect of EZH2 siRNA (si+) or a scrambled control siRNA (si-) on EZH2 protein levels in 
T265 and 90-8TL at 48h and 72 h post-transfection. (B) Cell proliferation monitored in time after 
transfection of T265 and 90-8TL with EZH2 siRNA (si+) or a scrambled control siRNA (si-). ẞ-actin 




Relative high expression of TOP2A in MPNST is 
associated with doxorubicin sensitivity. 
 
To verify whether TOP2A expression levels are increased in MPNST as was reported in the 
literature (9, 10) we determined the TOP2A mRNA levels in our paired FFPE and fresh frozen 
plexiform neurofibroma/MPNST sample sets. In both panels TOP2A mRNA expression was 
clearly induced in MPNST when compared to the levels detected in plexiform neurofibromas. 
In 7 out 9 paired FFPE samples TOP2A levels were significantly increased in the MPNST 
samples (Fig 5A). In the fresh frozen sample set TOP2A mRNA levels were on average 24-
fold higher in the MPNST than in the plexiform neurofibromas (Fig 5B).  In the cell line panel 
TOP2A mRNA levels in the MPNST cell lines were mostly equal or lower than the levels 
measured in the neurofibroma cell line Hs53.T, only the MPNST 90-8TL cell line exhibited 
relatively high TOP2A levels (Fig 5C). At the protein level, however, all MPNST cell lines 
displayed markedly higher TOP2A expression than the Hs53.T cells (Fig 5D). To examine 
whether the relatively high MPNST TOP2A levels translate into sensitivity to the TOP2A 
targeting chemotherapeutic drug doxorubicin we determined the sensitivity of the cell lines to 
this drug using an in vitro cytotoxicity (SRB) assay. All four NF1-associated MPNST cell line 
(sNF96.2, ST88-14, T265 and 90-8TL) and one sporadic MPNST cell line (STS26T) were 
more sensitive to doxorubicin than the neurofibroma Hs53.T cells, many of them displaying 
IC50 values of less than 50 ng/ml (Figs 6A,B). A comparison of TOP2A protein expression 
levels and the calculated IC50 values of the cell lines indicated a correlation, although not very 



















































































































































































































































































































































































































































































































































































Fig 6. Sensitivity of neurofibroma and MPNST cell lines to doxorubucin. (A) An in vitro cytotoxicity 
assay (SRB assay) was used to determine IC50 values (ng/ml) for doxorubucin of neurofibroma and 
MPNST cell lines after a 48h exposure to the drug. Graphs show cell viability as a function of doxorubucin 
concentration. Depicted is the average viability (n=4) of a representative experiment. (B) Listing of 
calculated IC50 values and correlation plot, with TOP2A protein expression levels on the Y-axis and IC50 





Given the limited number of therapeutic options for advanced MPNST patients, the 
identification of novel drug targets and the development of new treatments and treatment 
strategies is urgently needed.  In this study we analyzed the expression level of three potential 
drug targets BRD4, EZH2, and TOP2A in selected human MPNST and neurofibroma samples 
from the Erasmus MC tissue bank. Our sample set included both fresh frozen samples and a 
set of nine paired FFPE samples consisting of plexiform neurofibromas and MPNST that were 
resected from the same patient.  
 
With respect to BRD4, it has been shown that inhibition of this protein profoundly suppresses 
MPNST tumorigenesis and  tumor cell growth in a murine MPNST model (13). To confirm 
this putative key role of BRD4 in human MPNST pathogenesis, we evaluated the expression 
level of BRD4 in plexiform neurofibromas and MPNST samples. In addition, we studied the 
effect of BRD4 modulation by JQ1 on the cell viability of MPNST cell lines. In contrast to 
what has been reported for the MPNST mouse model (13), we did not find evidence for an 
increased expression of BRD4 in human MPNST samples when compared to plexiform 
neurofibromas. It must be noted, however, that we only examined a limited set tumor samples 
due to the rarity of MPNST. Additionally, in order to deal with tumor heterogeneity, it may be 
useful to examine multiple biopsies from the same tumor. Nevertheless our analyses of BRD4 
expression, either of FFPE or fresh frozen samples, do not indicate an overexpression in 
MPNST. In contrast,  previously reported overexpression of EZH2 and TOP2A  in MPNST 
could be convincingly demonstrated in our sample sets, using similar RT-PCR assays, 
indicating RNA quality is good. Alternatively, our inability to confirm BRD4 overexpression 
in the human MPNST setting may indicate that data acquired with genetically engineered 
animal models cannot always be easily translated to the human situation. It might be that these 
models do not recapitulate the full complexity of human cancers and/or there are unrecognized 
fundamental cross-species differences in the process of tumorigenesis (28, 29). Moreover, 
BRD4 inhibition by JQ1 treatment in our panel of MPNST cell lines indicated that they were 
less sensitive to JQ1 than the   primary murine skin-derived precursors (Nf1-/-, P53-/-) and 
MPNST cells derived thereof which display IC50 values of < 400 nM  (13). Although Patel et 
al. did use the human S462 MPNST cell line they did not present a dose-response curve from 
which an IC50 value could be deduced making a direct comparison with our results difficult.  
Likewise Patel et al. did not validate their findings regarding Brd4 overexpression in clinical 
tumor samples. Interestingly, de Raedt and colleagues provided evidence that BRD4 inhibition 
by JQ1 exerted only a modest, cytostatic effect on human MPNST cell lines and that only the 
combination of JQ1 with PD-901, a MEK-inhibitor, caused a tumor growth inhibition and 
regression (24).  
 
Zhang et al. demonstrated that EZH2 is overexpressed in MPNST and fulfils a key role in 
tumorigenesis (15, 18). Both downregulation of EZH2 by si/shRNA or pharmacological 
inhibition of EZH2 in the S462 (NF1-derived MPNST) and MPNST724 (spontaneous 
MPNST) cell lines severely affected cellular proliferation rates, induced apoptosis and 
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interfered with tumor formation in an MPNST724 xenograft model. We do confirm that EZH2, 
at least at the mRNA level, is more abundantly expressed in MPNST than in plexiform 
neurofibromas. However, when we examined the consequences of EZH2 downregulation on 
cellular proliferation in 90-8TL and T265 we did not observe any inhibitory effect, despite a 
significant EZH2 knockdown. It might be that the cell lines used by Zhang et al. respond 
differently to EZH2 knockdown or inhibition than the NF1-derived MPNST cell lines 90-8TL 
and T265 that we examined. It may be that knockdown of EZH2 is compensated for by other 
members of the PRC2 complex and/or the related EZH1. Our findings, however, do suggest 
that EZH2 functions may be dependent on cellular context. Importantly, it was recently 
reported that a substantial number of MPNST, irrespective of their origin (NF1-derived, 
spontaneous or radiation induced) exhibit an inactivated PRC2 complex due to somatic loss-
of-function mutations in SUZ12 and EED (24, 30, 31). Both SUZ12 and EED - just as EZH2 
- are integral parts of the PRC2 complex. It is not yet known what the consequences of such a 
PRC2 inactivation are for the remaining unaffected PRC2 complex subunits like EZH2. Is 
EZH2 still present in a protein complex and is EZH2 capable of fulfilling a biological role in 
this context or on its own? Perhaps the discrepancy between our findings and those of Zhang 
et al. (15) can be explained by different levels of PRC2 complex inactivation in the cell lines 
used. Translated to the clinic this would imply that before targeting EZH2 in the context of 
MPNST it is imperative to verify whether the PRC2 complex is in fact inactivated e.g. by 
determining the absence of H3K27 trimethylation (H3K27me3) in the tumor tissue. Only 
MPNST patients that display an active PRC2 complex may benefit from EZH2 inhibition.  
 
The enzyme TOP2A functions in maintaining DNA topology after replication. The cellular 
abundance of TOP2A is reported to determine the efficacy of anthracycline based 
chemotherapy in various cancers (32-37). The anthracycline doxorubicin, a widely used 
anticancer agent, can interfere with the catalytic cycle of TOP2A either by preventing its 
binding to DNA or by trapping TOP2A cleavage complexes and blocking DNA religation 
generating double strand DNA breaks (8). TOP2A levels in MPNST were reported to be 
upregulated due to amplification of the TOP2A gene (9, 10). Our results verified the abundant 
expression of TOP2A in MPNST and may explain why doxorubicin is widely used in the 
treatment of advanced MPNST patients. Though in general outcomes are poor, some patients 
may derive durable benefit from doxorubicin based treatment (7). When we determined the 
sensitivity of our neurofibroma and MPNST cell line panel for doxorubicin we observed that 
the MPNST cell lines exhibited the highest sensitivity in agreement with their higher TOP2A 
levels. Still the outcome of doxorubicin treatment in the clinic is poor for most MPNST 
patients perhaps due to the rapid activation of drug resistance mechanisms that diminish the 
efficacy of this chemotherapy. 
 
From this study, we tentatively conclude that the potential for effective therapeutic intervention 
in MPNST by targeting BRD4, EZH2 and TOP2A individually, is limited. However, this does 
not preclude the use of inhibitors in certain subpopulations of patients and/or in combination 
therapies. We strongly encourage other research groups to validate our findings and  are in 
favor of clinical studies involving patients as only these will ultimately prove the true value of 
BRD4, EZH2 and TOP2A inhibitors in the MPNST setting.  Last but not least further 
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investigations are needed into the biology of MPNST to identify  additional druggable disease 
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Malignant peripheral nerve sheath tumors (MPNST) are aggressive cancers that occur 
spontaneously (sporadic MPNST) or from pre-existing, benign plexiform neurofibromas in 
neurofibromatosis type 1 (NF1) patients. MPNSTs metastasize easily, are resistant to 
therapeutic intervention and are frequently fatal. The molecular changes underlying the 
transition to malignancy in the NF1 setting are incompletely understood. Here we investigate 
the involvement of microRNAs in this process. Using an RT-PCR platform microRNA 
expression profiles were determined from a unique series of archival paired samples of 
plexiform neurofibroma and MPNST.  At least 90 differentially expressed microRNAs 
(p<0.025; FDR<10%) were identified between the paired samples. Most microRNAs (91%) 
were found downregulated and 9% of the microRNAs were upregulated in MPNST. Based on 
the fold changes and statistical significance three downregulated microRNAs (let-7b-5p, miR-
143-3p, miR-145-5p) and two upregulated microRNAs (miR135b-5p and miR-889-3p) were 
selected for further functional characterization. In general their expression levels were 
validated in a relevant cell line panel but only partly in a series of unpaired fresh frozen tumor 
samples containing plexiform neurofibromas, atypical neurofibromas and MPNSTs. As part 
of the validation process we also determined and analyzed microRNA expression profiles of 
sporadic MPNSTs observing that microRNA expression discriminates NF1-associated and 
sporadic MPNSTs emphasizing their different etiologies. The involvement of microRNAs in 
tumorigenesis and cancer progression was examined in NF1-derived MPNST cell lines 
through modulating microRNA levels by transient transfection of microRNA mimics or 
inhibitors. The effects of microRNAs on cellular proliferation, migration, invasion and Wnt/ẞ-
catenin signaling were determined. Our findings indicate that, some of the selected 
microRNAs affect migratory and invasive capabilities and Wnt signaling activity. It was 
observed that the functional effects upon microRNA modulation are distinct in different cell 
lines. From our study we conclude that miRNAs play essential regulatory roles in MPNST 





Neurofibromatosis type 1 (NF1) is a relatively common autosomal dominant disorder which 
is caused by inherited or sporadic mutations in the NF1 gene 1-3. The NF1 gene encodes the 
tumor suppressor neurofibromin 1 that functions as a negative regulator of Ras signaling by 
its GTPase- activating protein (GAP) domain. The partial inactivation of neurofibromin 1 seen 
in NF1 patients can cause variable symptoms affecting the skin, bone and the nervous system.  
Moreover, the disease is associated with an increased risk of benign and malignant tumor 
formation. Almost all NF1 patients develop cutaneous neurofibromas and in many instances 
also deeper seated plexiform neurofibromas. These benign tumors are believed to originate 
from the Schwann cell lineage i.e. mature Schwann cells or Schwann cell precursors 4,5 and 
are characterized by a biallelic inactivation of the NF1 gene 1,6. Approximately 10% of NF1 
patients develop malignant peripheral nerve sheath tumors (MPNSTs) usually in the context 
of pre-existing plexiform neurofibromas. MPNST are highly aggressive tumors that are largely 
responsible for the reduced life expectancy these patients face 7-9. Early metastasis, poor 
prognosis, and resistance to therapeutic interventions are common clinical features of this 
cancer. While patients with non-metastatic disease may benefit from surgical resection and 
radiation, many patients relapse. These patients, and also those initially presenting with 
advanced disease, face a poor prognosis as there are only a limited number of systemic agents 
available for these patients such as doxorubicin, ifosfamide and pazopanib. The relatively 
modest anti-tumor activity of these agents translates in a median overall survival of 
approximately one year 10,11. A better understanding of the essential molecular mechanisms 
underlying plexiform neurofibroma transformation to MPNST is crucial to reveal NF1 patients 
who are at risk to develop MPNST and to identify new targets for treatment.  
 
MicroRNAs (miRNAs) are a class of small non-protein coding RNAs of approximately 19-26 
nucleotides in length that function in post-transcriptional gene regulation. They generally 
operate by binding in the context of the RNA induced silencing complex (RISC) to the 3’ 
untranslated region of target mRNAs. MiRNA binding, through base pairing between the 
miRNA and mRNA, cause mRNA degradation and/or inhibition of translation 12,13. Over the 
past two decades it became clear that miRNAs fulfil pivotal roles in a wide variety of 
biochemical and physiological processes and are intimately involved in numerous pathological 
processes including cancer 14-17. A dysregulated miRNA expression profile is a key 
characteristic of cancer and can be exploited for diagnostic purposes. There is ample evidence 
that miRNAs can have oncogenic or tumor suppressive properties. However, in many instances 
the extent to which individual – aberrantly expressed – miRNAs contribute to carcinogenesis 
and cancer progression and/or affect treatment response is not fully understood. A limited 
number of miRNA profiling studies examined human neurofibroma and NF1-derived MPNST 
tumor samples and implicated the involvement of several miRNAs in the malignant 
transformation of plexiform neurofibroma to MPNST 18-21. Although of interest, these studies 
are difficult to compare as different miRNA detection platforms were used, variable numbers 
of unpaired tumor samples were examined and only a few miRNAs were functionally 
characterized.  Here we analyzed miRNA expression, using an established and highly 
reproducible RT-PCR procedure, in a unique series of paired human archival tumor samples 
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of plexiform neurofibroma and MPNST. Each individual neurofibroma/MPNST pair being 
derived from the same NF1 patient. The expression of a selected set of differentially expressed 
miRNAs was validated using a well-characterized neurofibroma/MPNST cell line panel as 
well as fresh frozen samples of plexiform neurofibromas, atypical neurofibromas and MPNST.  
To understand how these miRNAs affect carcinogenesis and/or MPNST progression we 
modulated their expression levels in MPNST cell lines and assessed their impact on cellular 
proliferation, migration and invasion and Wnt/β-catenin signaling.   
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Materials and Methods 
 
Tumor samples  
 
Neurofibromatosis type 1 patients from which both archival plexiform neurofibroma as well 
as MPNST resection samples were available were identified in the Erasmus Medical Center 
patient files. Formalin-fixed paraffin-embedded (FFPE) tissue blocks were collected, from the 
Erasmus MC Tissue bank, of a set of nine neurofibroma-MPNST pairs (see Supplementary 
Table 1 for patient and tumor characteristics). In addition, ten FFPE tumor tissue blocks were 
collected that were derived from patients diagnosed with sporadic MPNST (Supplementary 
Table 2). Fresh frozen tumor samples from plexiform neurofibroma (n=7), atypical 
neurofibroma (n=4) and NF1-associated MPNST (n=11) (Supplementary Table 3) from the 
Erasmus MC tissue bank were included for validation purposes. Hematoxylin-eosin-stained 
sections of these samples were examined by an expert pathologist at the Erasmus MC (RMV) 
to confirm the initial histopathological diagnosis using criteria as described before 22,23 in 
accordance with the 2016 WHO classification of Tumours of the Central Nervous System 24. 
The experimental protocol was submitted for review to, and approved by, the Medical Ethics 
Committee Erasmus MC of Rotterdam (MEC-2016-213). All experimental procedures, 
including the use of human tissues samples, were performed in accordance with the relevant 
guidelines and regulations, with all researchers adhering to the code of conduct for medical 
research as laid out by the council of the Federation of Dutch Medical Scientific Societies 
(https://www.federa.org/codes-conduct). The use of anonymous or coded left-over material for 
scientific purposes is part of the standard treatment agreement with patients and therefore 




The human NF1-associated MPNST derived cell lines 90-8TL, ST88-14 and the sporadic 
MPNST derived STS26T cell line were a kind gift of Dr. Eduard Serra (Institute of Predictive 
and Personalized Medicine of Cancer/IMPPC, Barcelona, Spain). The sNF96.2 cell line (NF1-
derived MPNST) and the HS53T cell line (cutaneous neurofibroma) were obtained from the 
American Type Culture Collection (ATCC). All cell lines were routinely cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco Life Technologies) supplemented with 
10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2. All cell cultures were regularly screened for 
mycoplasma infection. Short Tandem Repeat (STR) profiles of the cell lines were established 
for authentication purposes (Supplementary Fig. 1) and were matched to source profiles at the 
ATCC, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) or the literature 







Total RNA was extracted from 5-6 20 µm sections from each FFPE tumor sample using the 
RecoverAllTM total nucleic acid isolation kit (Ambion / Life Technologies) according to the 
manufacturer’s recommendations. RNAbee (Tel test Inc.) was used to isolate total RNA from 
cell pellets and fresh frozen tumor tissue samples following standard protocols. The quality 
and concentration of all the RNA preparations were examined using a Nanodrop-1000 




The miRNA expression profiles were determined in FFPE samples using TaqMan® Low 
Density Array (TLDA) Human MicroRNA Cards (A card v2.0, B card v3.0; Applied 
Biosystems/Thermo Fisher Scientific) capable of detecting 756 distinct human miRNAs 
essentially as previously described 25. In brief: Two pools of cDNA were prepared using 
Megaplex™ RT Primers Human Pools (pool A v2.1, pool B v3.0) and a Taqman® microRNA 
reverse Transcription kit (Applied Biosystems/ Thermo Fisher Scientific). Next, a pre-
amplification step was carried out using Megaplex™ PreAmp Primers Human Pools (pool 
Av2.1, pool B v3.0) together with the Taqman™ PreAmp master-mix (Applied 
Biosystems/Thermo Fisher Scientific). The  resulting products were further amplified using 
Taqman™ Universal PCR Master-Mix No AmpErase® on human microRNA A and B cards 
in a 7900HT Fast Real-Time PCR system (Applied Biosystems/Thermo Fisher Scientific). The  
expression (CT value ) of a specific miRNA in a sample was normalized to the median CT of 
all detectable miRNAs in that sample. Subsequently the normalized relative expression (2-ΔCT) 
was calculated for each miRNA. The normalized miRNA expression data were log 2 
transformed and median centered to acquire the relative expression values that were used for 
hierarchical clustering analyses using Cluster-3.0 and Java TreeView for visualization. The 
clustering was based on the uncentered correlation as a distance metric using average linkage. 
A Student T-test (paired) was used to determine statistical significance between distinct groups 
of expression data and the Benjamini-Hochberg false discovery rate (FDR) was used to control 




The expression level of individual miRNAs was determined using the TaqMan® MiRNA 
Assays Technology (Applied Biosystems/Thermo Fisher Scientific) in a 
neurofibroma/MPNST cell line panel and fresh frozen tumor samples.  In brief: Total RNA 
(50 ng) was reverse transcribed in a multiplex reaction using specific miRNA primers from 
the TaqMan® MiRNA Assays and reagents from the TaqMan® MiRNA Reverse Transcription 
Kit (Applied Biosystems/Thermo Fisher Scientific) according to the manufacturer’s protocol. 
The resulting cDNA was used as input in a quantitative real-time PCR (qPCR) using a miRNA 
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specific primer/probe mix together with the TaqMan® Universal PCR Master Mix No 
AmpErase® UNG (Applied Biosystems/Thermo Fisher Scientific) using the 7500 Fast Real-
Time PCR systems (Applied Biosystems/Thermo Fisher Scientific). The qPCR data were 
analyzed using SDS software (version 2.4, Applied Biosystems/Thermo Fisher Scientific). A 
standard dilution series of a cDNA sample-pool was included on every plate allowing for the 
absolute quantification of the miRNA expression.  
 
The mRNA expression of Wnt target genes was determined by RT-PCR using the TaqMan® 
Technology (Applied Biosystems/Thermo Fisher Scientific).  In brief: Total RNA (1 µg) was 
used as input for a reverse transcription reaction using a high capacity cDNA reverse 
transcription kit (Applied Biosystems/Thermo Fisher Scientific) according to protocols of the 
manufacturer. The cDNA was used as input in a PCR reaction using primer/probe 
combinations from the following Taqman® gene expression assays  (LEF1, assay ID: 
Hs01547250_m1; MSX2, assay ID: Hs00741177_m1; SOX9, assay ID:Hs00165814_m1; 
TWIST1, assay ID: Hs00361186_m1) and Taqman® Universal PCR master mix using the 
7500 Fast Real-Time PCR system (all obtained from Applied Biosystems/Thermo Fisher 
Scientific) according to the manufacturer’s recommendations.  Three housekeepers (GAPDH, 
HPRT and PPIA) were used for normalization purposes using the comparative CT-method 26. 





Human MPNST cells were plated in 96-well plates at a concentration of 2 - 18 x 103 cells/well 
(SNF96.2); 2 - 10 x 103 cells/well (ST88-14) and 2 -10 x 103 cells/well (90-8TL) in a total 
volume of 200 μl of standard cell culture medium without antibiotics. After 24 h cells were 
transfected with 50 nM MiRIDIAN microRNA mimics (Dharmacon) of let7b-5p, miR-143-
3p, miR-145-5p and miR-29c-3p or 50 nM MiRCURY LNATM inhibitors (Exiqon) of miR-
135b-5p and miR-889-3p. As controls a scrambled miRNA mimic Negative control #1 
(Dharmacon) and the miRCURY LNATM inhibitor Negative Control (Exiqon) were used. 
DharmaFECT I was used as a transfection reagent. Transfection conditions were optimized 
(transfection efficiency > 90%) for each of the cell lines using a fluorescently labelled miRNA 




Twenty-four hours prior to transfection, cells were plated in a 96-well plate. The next day the 
cells were transfected at approximately 40-50% confluency with selected miRNA 
mimics/inhibitors or appropriate controls. Cell viability was assessed by a sulforhodamine B 
(SRB) assay at 72 h post-transfection essentially as described previously27. In short: cells were 
fixed by 10% TCA in PBS, washed and stained by 0.4% SRB in 1% acetic acid for 15 min, 
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washed in 1% acetic acid and dried. Color was dissolved in Tris-Base after which the A540nm 




Wound healing kinetics: Twenty-four hours prior to transfection, cells were plated in a 96-well 
ImageLockTM plate (Essen BioScience Ltd.). The next day the cells were transfected with 
selected miRNA mimics/inhibitors or appropriate controls. At 24 h post-transfection, all 96 
wells were scratched simultaneously in the central axis of the individual wells using the 
WoundMakerTM (Essen Bioscience Ltd.). A live-cell imaging system, IncuCyte (Essen 
BioScience Ltd.) was used to automatically monitor the kinetics of cell migration every 2 hours 
for a total duration of 26 h during which cells migrate from the scratch edges into the wound 
area.  
 
Cell-speed measurements:  Twenty-four hours prior to transfection, cells were plated in a 96-
well CellCarrierTM-96 Ultra microplate (PerkinElmer). The next day the cells were transfected 
with selected miRNA mimics or appropriate controls. At 24 h post-transfection cells were 
imaged at 2 h intervals in an Opera Phenix™ HCS system (PerkinElmer) for 40 h. Software 
(Harmony® High Content Imaging and Analysis Software, PerkinElmer) was used to calculate 




Cells were cultured in a 6-well plate and transfected with selected miRNA mimics/inhibitors 
or appropriate controls. At 24 h post-transfection the cells were harvested by mild 
trypsinization, resuspended in DMEM supplemented with 2.5% FBS and plated into the 
IncuCyteTM ClearView 96-well insert (Essen BioScience Ltd.) at a concentration of 2 x 103 
cells/well (SNF96.2); 2 x 103 cells/well (ST88-14) and 7.5 x 103 cells/well (90-8TL). Prior to 
plating the transfected cells, the IncuCyte ClearView insert membranes were coated with 50 
μg/ml Matrigel (BD Biosciences). The inserts were subsequently placed in a 96-well plate 
containing DMEM supplemented with 10% FBS and incubated under standard cell culture 
conditions. An IncuCyte live-cell imaging system (Essen BioScience Ltd.) was used to capture 
cell invasion monitoring and quantifying invading cells through the matrigel coated 
membranes every two hours for a total period of 67 h.  
 
Wnt reporter assay 
 
Wnt/β-catenin signaling activity was determined by a β-catenin/TCF reporter assay in a two-
step transfection process. In brief: SNF96.2, ST88-14 and 90-8TL cell lines were plated in 24-
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well plates in culture medium without antibiotics. When the cells reached 60 – 70% confluency 
they were transfected with MiRCURY LNATM inhibitors (Exiqon) of miR-135b-5p, miR-889-
3p or a miRCURY LNATM inhibitor Negative Control (Exiqon) in a final concentration of 50 
nM using Dharmafect I. After 24 h the cells were co-transfected with 250 ng of the TOP-Flash 
or FOP-Flash firefly luciferase reporter constructs 28 and 25 ng of a SV40-Renilla luciferase 
expression (for normalization purposes) using FuGene ®HD (Promega). Eight hours post-
transfection the cells were stimulated with 25% L-control medium in DMEM or 25 % L-
Wnt3A medium in DMEM and left to incubate for 16 h after which the cells were lysed and 
assayed for firefly and Renilla luciferase activities using the Dual-Luciferase reporter assay 





Plexiform neurofibromas can be distinguished from 
MPNST by their microRNA expression profile. 
 
To study the involvement of miRNAs in the malignant transition of benign plexiform 
neurofibromas into MPNST we determined the miRNA expression profiles of a unique series 
of nine paired plexiform neurofibromas and MPNST samples. Each plexiform neurofibroma / 
MPNST pair was derived from the same NF1 patient. An unsupervised hierarchical clustering, 
based on the expression of all detectable miRNAs in these paired samples, already grouped 
most of the benign plexiform neurofibromas and MPNSTs in distinct clusters (Supplementary 
Fig. 3). A supervised clustering analysis using the 90 most significant differentially expressed 
miRNAs (p<0.025; FDR<10%) between neurofibromas and MPNSTs grouped the samples 
into clearly separate clusters (Fig. 1, Supplementary Table 4). The majority (82 out of 90; 91%) 
of the differentially expressed miRNAs were found to be downregulated in the MPNST group 
in comparison to the plexiform neurofibromas. The downregulated miRNAs include members 
of well-known cancer related miRNA clusters like the miR-23/27/24 clusters on chromosome 
9-q22.32 and 19-p13.12, the miR-143/145 cluster on 5-q33.1, the miR-29b-1/29a and miR-
29b-2/29c clusters on chromosome 7-q32.3 and 1-q32.2, respectively. In addition, 5 members 
of the let-7 family, let-7a/b/c/d/e were found downregulated in MPNST. Only 8 (9%) of the 
miRNAs exhibited a higher expression in the MPNST samples than in neurofibromas, these 
include miR-135b, miR-889, miR-493, miR-433 and miR-541, the last four all belonging to a 
large miRNA cluster on the long arm of chromosome 14 (14-q32.31). Particularly, miR-135b 
and miR-541 are aberrantly expressed in the MPNST setting with a 52-fold and 20-fold 


























































































































































































































































































































































































































































































































































































































Validation of differentially expressed microRNAs 
between plexiform neurofibromas and MPNST in a 
cell line panel and fresh frozen tumor samples. 
 
It was investigated whether the differential expression of a selected set of miRNAs could be 
validated in a well-characterized cell line panel and additional, unpaired fresh frozen 
neurofibroma and MPNST samples. Taking statistical significance (p<5x10-4; FDR<1%), fold-
difference (>3 in at least 75% of the sample pairs) into account as well as the reported 
involvement of miRNAs in cancer, we selected the following miRNAs for further validation 
and subsequent functional studies miR-145-5p, miR-143-3p, miR-139-5p and let-7b-5p all 
downregulated in MPNST and miR-135b-5p and miR-889-3p as representatives of the 
upregulated miRNAs (Fig. 1, Supplementary Tables 4 and 5). When considering the 
expression of the selected miRNAs in the individual NF-MPNST samples pairs it was noted 
that the fold-difference of the up or down-regulation varies considerable between different 
pairs (Supplementary Table 5). Using quantitative PCR, we could validate the expression of 
the selected miRNAs as shown in Fig. 2A. MiR-145, let-7b, miR-143 - and to a lesser extent 
miR-139-5p - were all downregulated in the MPNST cell lines STS26T, sNF96.2, ST88-14 
and 90-8TL compared to their expression level in a cutaneous neurofibroma cell line Hs53.T. 
Conversely, miR-135b found upregulated in most MPNST cell lines. MiR-889 was clearly 
upregulated in ST-88-14 and 90-8TL but downregulated in sNF96.2 and the sporadic MPNST 
cell line STS26T. general, these results (Fig. 2C) confirm our miRNA profiling findings and 
identify the MPNST cell lines as representative models for this malignancy. As the expression 
distribution between neurofibroma and MPNST for miR-139-5p reflected our profiling results 
the least, we omitted this miRNA from further analyses. As additional validation we 
determined the expression levels of the selected miRNAs in fresh frozen samples from a 
plexiform neurofibroma / MPNST sample pair derived from the same patient (Fig. 2B). In 
agreement with our previous observations we demonstrated downregulation of miR-145, miR-
143 and let-7b whereas miR-135b and miR-889 were upregulated in the MPNST sample. We 
also determined the expression levels of the selected miRNAs in a larger unpaired panel of 
fresh frozen tumor samples consisting of plexiform neurofibromas (n=6), atypical 
neurofibromas (n=4) and MPNSTs (n=10) (Fig. 3). The expression level of the miRNAs in 
atypical neurofibroma samples is not significantly different from the expression observed in 
plexiform neurofibromas. A comparison between the miRNA expression levels in MPNST 
and neurofibromas indicated a significant downregulation in the MPNST group of let-7b 
(p<0.01) and of miR-145 when the expression levels in MPNST were compared to levels in 
atypical neurofibromas (p<0.05). A comparison of miR-145 levels between MPNST and 
plexiform neurofibromas was borderline significant (p=0.0572). Likewise, the expression of 
miR-143 between MPNST and atypical neurofibromas was borderline significant (p=0.0584).  
No significant statistical difference between sample groups was observed for miR-889, miR-
143 and miR-135b expression. The high variability observed in the expression levels of the 
selected miRNAs, particularly in the MPNST samples, most likely reflects tumor 
heterogeneity and may obscure differences. This problem may be partly overcome by 













































































































































































































































































































































































































































































































































































































Fig. 3 Expression level of selected microRNAs in unpaired fresh frozen plexiform neurofibroma, 
atypical neurofibroma and MPNST samples. A quantitative RT-PCR was used to determine 
miRNA levels of miR-145-5p, let-7b-5p, miR-143-3p, miR135b-5p and miR-889-3p in unpaired 
fresh frozen NF1-derived MPNST (n=10), plexiform neurofibroma (NF; n=6) and atypical 
neurofibroma (Atyp NF; n=4). Relative expression is depicted using Box-Whisker plots with boxes 
showing 1st to 3rd quartile with the median marked by a horizontal line. A Mann Whitney U test was 
used to determine statistical significance; p- value <0.01 (**), p-value <0.05 (*). 
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NF1-associated MPNST and sporadic MPNST 
display distinct miRNA expression profiles. 
 
To assess whether the selected miRNAs are specifically dysregulated in NF1-derived MPNST, 
we examined miRNA expression in 10 archival sporadic MPNST samples. A comparison 
between the miRNA profiles observed in the sporadic MPNST and the NF1-derived MPNST 
revealed many differentially expressed miRNAs (Fig. 4, Supplementary Table 6, 
Supplementary Fig. 4) emphasizing these tumor types have a different etiology and possibly a 
different biology. A cluster analysis using the 45 most significantly differentially expressed 
miRNAs (p<0.03, FDR<10%) completely discriminated the two MPNST types (Fig. 4). Very 
few of the miRNAs identified in the plexiform neurofibroma-MPNST comparison, and none 
of the selected miRNAs, were detected in the sporadic MPNST – NF1-derived MPNST 
comparison. Apparently, the selected miRNAs were not differentially expressed between 
sporadic and NF1-derived MPNST. Therefore, we cannot rule out that the selected miRNAs 
are also aberrantly expressed in sporadic MPNST and play a role in carcinogenic processes in 

































































































































































































































































































































































































































































MicroRNAs affect migratory and invasive capacity 
of MPNST cell lines. 
 
The selected miRNAs that are dysregulated in NF1-associated MPNST may contribute to the 
process of tumorigenesis and metastasis. All have been linked to various aspects of 
carcinogenesis in other cancers. The clustered miR-143 and miR-145 genes are widely 
regarded as tumor suppressors in epithelial tumors 29-32 and were indicated as having a critical 
role in tumor stroma 33,34. MiR-135b has been implicated in the progression of several cancers 
35-37 and let-7b is considered a tumor suppressor miRNA 38. In vitro experiments were 
conducted to examine the functional role of the selected miRNAs and their effect on cellular 
proliferation, migration and invasion. To that end, transiently, the expression levels of let-7b, 
miR-145 and miR-143 were restored and miR-135b and miR-889 levels were reduced, in 
MPNST cell lines. As a control we included a miR-29c mimic. This miRNA was reported by 
Presneau et al. to be reduced in MPNST and to affect migration and invasion, but not 
proliferation 20.  
 
First, we focused on cellular proliferation using an SRB assay to assess the effects of miRNA 
modulation on cell viability. It was observed that none of the miRNA mimics or inhibitors 
significantly and consistently affected proliferation with the exception of miR-29c 
overexpression in sNF96.2 which stimulated cell proliferation (Supplementary Fig. 5). We 
next assessed whether the selected miRNAs affect the migratory and invasive capacity of the 
tumor cells. We performed a scratch assay to measure the migration potential of the transfected 
MPNST cells. Fig. 5 depicts representative results on the kinetics of migration in sNF96.2 and 
ST88-14 transfectants obtained by a live-cell imaging system. Most miRNA mimics and 
inhibitors did not significantly interfere with the migratory capacity of the MPNST cells (Fig. 
5A, C). However, a clear reduction of the migration rate was observed in sNF96.2 cells 
transfected with let-7b (Fig. 5B) and in ST88-14 cells transfected with miR-29c (Fig. 5D). 
None of the miRNA mimics and inhibitors had an effect on the migration capacity of 90-8TL 
cells (Supplementary Fig. 6A). These observations were confirmed when we determined the 
average cell speed as a measure for migratory capacity using a different cell imaging system 
(Supplementary Fig. 7).  
 
Next, we examined the effect of the selected miRNAs on the invasive capacity of MPNST 
cells in a cell invasion assay. The MPNST cell lines sNF96.2 and ST88-14 were transfected 
and seeded onto 96-well invasion plates containing a matrigel coated membrane. Invasion of 
cells was quantitatively monitored by live-cell imaging in time. A strikingly reduced invasive 
capacity was observed in ST88-14 transfected with miR-135b (p=0.001) and miR-889 
(p=0.028) inhibitors (Fig. 6C). These effects, however, were not seen in sNF96.2 transfectants 
(Fig. 6A) or 90-8TL transfectants (Supplementary Fig. 6B). In sNF96.2 cells, transfection with 
let-7b (p=0.007) and miR-29c (p=0.007) mimics, and to a lesser extent with miR-145 
(p=0.047) resulted in reduced invasiveness (Fig. 6B). In contrast, miR-143 (p=0.00006) and 
miR-145(p=0.005) mimics appeared to boost invasion in ST88-14 (Fig. 6D). We conclude that 





Fig. 5 – Effects of let-7b and miR-29c on cell migration of the MPNST cell lines sNF96.2 and ST88-
14. The NF1-associated MPNST cell lines sNF96.2 and ST88-14 were transfected with scrambled (LNA 
control),  miR-135b and miR-889 inhibitors or with a scrambled (mneg control), miR-143, miR-145, let-
7b and miR-29c mimics. (A, C) Scratch assay after which cell migration is monitored every two hours for 
26 h using a live-cell imaging system (IncuCyte; Essen Bioscience Ltd.). (B, D) Micrographs illustrating 
the effects of let-7b and miR-29c mimics on cell migration in sNF96.2 and ST88-14, respectively. The 
individual panels show the situation directly after scratching (left panels), at 14 h (middle panels) and after 
26 h (right panels). Depicted are representative images and graphs of three independent experiments, in 








Fig. 6 – Effects of selected miRNA mimics on invasive capacity of the MPNST cell lines sNF96.2 and 
ST88-14. (A-D) The NF1-associated MPNST cell lines sNF96.2 and ST88-14 were transfected with 
scrambled (LNA control), miR-135b and miR-889 inhibitors or with a scrambled (mneg control), miR-
143, miR-145, let-7b and miR-29c mimics. Invasive capacity was monitored every two hours for 67 h 
using a live-cell imaging system (IncuCyte). Y-axis indicates the “Total phase object area normalized to 
the initial top value” as a measure for the invading cell population. Depicted are representative graphs of 
xx independent experiments, points in graphs display average values ± SD (n=3). A Mann Whitney u 
test was used to determine statistical significance comparing the last 10 datapoints in each series. 
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miR-135b and miR-889 modulate Wnt/β-catenin 
signaling in MPNST cells. 
    
Recently the canonical Wnt/β-catenin signaling pathway has been identified as driver pathway 
of both benign neurofibromas and MPNST 39,40. Moreover, miR-135b was reported to target 
multiple negative regulators of Wnt like Adenomatous Polyposis Coli (APC) 36. Likewise, 
miR-889, another overexpressed miRNA in MPNST, was also predicted to target both APC 
according to Targetscan version 7.1. We therefore examined whether miR-135b (on average 
52x higher in MPNST) and miR-889 (on average 3x higher in MPNST) (Supplementary Tables 
4 and 5) are capable of modulating Wnt signaling activity in the MPNST setting. sNF96.2, 
ST88-14 and 90-8TL were transfected with miR-135b or miR-889 inhibitors. Next, we 
determined Wnt/ẞ-catenin signaling activity using a TCF/ ẞ-catenin reporter assay. It was 
noticed that Wnt/ ẞ-catenin activity upon induction with Wnt ligand was highest in ST88-14 
(Fig. 7A) and 90-8TL (Supplementary Fig. 6C) with relatively low Wnt activity being 
measured in sNF96.2 (Fig. 7A). Transient reduction of miR-135b and miR-889 expression 
significantly impaired the induction of Wnt/ ẞ-catenin signaling activity in ST88-14 (Fig. 7A). 
No significant effects were observed in the 90-8TL despite the relatively high Wnt activity 
levels observed in this cell line (Supplementary Fig. 6C). A small but significant reduction of 
Wnt activation was seen in miR-889 inhibitor transfectants of sNF96.2 but not in the miR-
135b inhibitor transfectant (Fig. 7A). To verify that Wnt is indeed affected the mRNA 
expression levels of Wnt target genes LEF1, MSX2, SOX9 and TWIST1, all genes expressed 
in MPNST and Schwann cells39, were determined by quantitative PCR. ST88-14 cells that 
display active Wnt signalling (Fig. 7A) were transfected with control, miR-135b and miR-889 
inhibitors. Figure 6B indicates that miR-135b inhibition consistently showed a trend of 
lowering the expression level of the Wnt target genes compared to a control transfection 
although without reaching statistical significance. Inhibition of miR-889 gave rise to similar 
results but the reduction in expression of the Wnt targets seemed stronger, more persistant and 
reached statistical significance. We conclude that both the overexpressed miR-135b and miR-






Fig. 7 – Effect of miRNA modulation on Wnt signaling capacity in ST88-14 and 90-8TL cell lines. 
The NF1-associated MPNST cell lines sNF96.2 and ST88-14 were transfected with scrambled (LNA 
control), miR-135b and miR-889 inhibitors. (A) Wnt/ẞ-catenin signaling activity upon induction by Wnt 
ligand was determined using a β-catenin/TCF reporter assay. Depicted are average values ± SD (n= 9) (B) 
mRNA expression levels measured by quantitative RT-PCR of Wnt target genes (LEF1, MSX2, SOX9, 
TWIST1). Depicted are normalised average expression values ± SD (n=4-6). In both (A) and (B) a Mann 





MPNSTs are highly aggressive tumors with a dismal prognosis for those confronted with 
advanced disease 10,11. Half of these tumors arise in the context of NF1 from benign pre-
existing plexiform neurofibromas 7,41. Genetic aberrations associated with this transformation 
include mutations in CDKN2A 42 and TP53 43 and the recently disovered loss-of-function 
mutations in SUZ12 and EED, essential components of the PRC2 complex 44-46. However, the 
precise molecular mechanisms underlying this maligant transition are still unclear. We 
investigated the involvement of miRNAs in the tumorigenesis and progression of MPNST. 
 
MiRNAs are intricately connected to cancer and play critical roles in cancer gene regulation 
and diverse aspects of tumorigenesis 14-17. Until now only few studies addressed the miRNA 
involvement in neurofibroma and MPNST biology 18-21. All studies reported clear differences 
in miRNA expression between plexiform neurofibromas and MPNST when unpaired tumor 
samples were analyzed. However, the functional significance and pathological roles of 
dysregulated miRNAs in the context of MPNST are not, or poorly studied. In 2010, Chai et al. 
were the first to point out the downregulation of let7a/b in MPNST cells and their effect on 
MPNST cell invasiveness 18. We as well observed the downregulation of multiple let-7 family 
members, including let7a/b in MPNST and noticed that let-7b expression interfered with 
cellular migration and invasion in NF1-derived MPNST cell lines. Let-7 family members are 
known to target Ras 47 it might therefore be that their relatively low levels in MPNST facilitate 
Ras signaling. Presneau et al. described a reduction of miR-29 members, most notably miR-
29c, in MPNST 20. They demonstrated that miR-29c played a role in tumor progression by 
controlling migration and invasion via the regulation of the matrix metalloproteinase-2 
(MMP2) 20. Our findings also indicated significantly lowered levels of miR-29a/b/c and we 
confirmed – although not in all NF1-derived MPNST cell lines – the effects of miR-29c on 
migration and invasion 48. Supplementary Table 7 presents an overview of all miRNAs that 
were found dysregulated in NF1-associated MPNST in comparison to plexiform 
neurofibromas in multiple studies. Note that in general only few miRNAs were found 
upregulated in MPNST and that most differentially expressed miRNAs display a reduced 
expression level in MPNST.  
 
By comparing the miRNA expression profiles of a unique series of paired samples of 
neurofibromas and MPNST, we defined a group of miRNAs that are aberrantly expressed in 
NF1-derived MPNST. From the 90 miRNAs that were identified we chose six miRNAs to 
examine their functional role in the pathogenesis of MPNST. MiR-143/145, let7b, miR-139-
5p, miR135b, and miR-889 were among the top 15 of differentially expressed miRNAs. 
(Supplementary Table 4). All, with the exception of miR-889, were also reported as 
misexpressed in MPNST by other researchers (Supplementary Table 7). However, none of the 
miRNAs we examined, with the exception of let-7b, has been studied in MPNST. We were 
able to validate the reduced expression of let-7b, miR-143/145 and the increased expression of 
miR-135b in MPNST using a relevant cell line panel. The upregulation of miR-889 was only 
observed in two NF1 associated MPNST cell lines (ST88-14 and 90-8TL) and not in sNF96.2 
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and the sporadic MPNST cell line STS26T. The increased expression of miR-889 in MPNST, 
which is less striking than that of miR-135b, may be more variable and occur only in a subset 
of tumors. When we examined the expression of the selected miRNAs in an unrelated series 
of unpaired fresh frozen plexiform neurofibroma, atypical neurofibroma and NF1-derived 
MPNST samples the down or upregulation of most selected miRNAs could not be firmly 
established. This may be due to the limited number of samples, together with the highly 
variable expression of the miRNAs examined in the MPNSTs. These results, however, do 
emphasize the value of paired samples and the need to analyze well-characterized and 
adequately sized cohorts to account for tumor heterogeneity.  
 
A direct comparison between sporadic MPNST and NF1-derived MPNST revealed that these 
two tumor types could be completely distinguished on the basis of their miRNA expression 
profiles. This result contrasts with the findings of Holtkamp et al. who reported that sporadic 
and NF1-derived MPNST could not be distinguished by their mRNA expression patterns 49. 
However, this study only examined the expression of 558 genes comparing 6 sporadic 
MPNSTs with 4 NF1-derived MPNST, due to its limited set-up differences may have been 
missed. 
 
Functional experiments initially focused on proliferation, migration and invasion, all key 
elements of carcinogenesis and cancer progression. It was uncovered that the selected miRNAs 
did not affect proliferation but their overexpression (miR-143, miR-145 and let-7b) or 
inhibition (miR-135b, miR-889) interfered with migration and invasion although not all cell 
lines responded in a similar fashion and/or with equal intensity (Figs. 4 and 5; Supplementary 
Figs. 6 and 7). Recently Watson et al. implicated the Wnt/β-catenin signaling pathway to fulfil 
an essential role in both neurofibromas and MPNST showing that inhibition of Wnt signaling 
by small molecules reduced viability and induced apoptosis 40. The precise biological basis of 
Wnt/ β-catenin signaling activation is only partly known and involves the downregulation of 
members of the β-catenin destruction complex and the expression of R-spondin 2 potentiating 
Wnt signaling. When we measured Wnt/β-catenin signaling activity using a β-catenin/TCF 
reporter system we observed that cell lines do show a different Wnt-pathway activation upon 
exposure to Wnt ligand with high activity in ST88-14 and 90-8TL and low activity in sNF96.2. 
This difference may be caused by the variable expression levels of Wnt pathway genes in 
different cell lines as reported by Luscan et al. 39. Transient inhibition of both miR-135b and 
miR-889 using antisense inhibitors reduced the capacity of ST88-14 to induce Wnt signaling 
upon stimulation. In agreement with this observation is the fact that miR-135b and miR-889 
inhibitors impair invasion of ST88-14 cells as Wnt signaling has been shown to be involved in 
invasion in many cancer cells 50. No clear effects were seen on proliferation and migration of 
this cell line upon miR-135b and miR-889 inhibition. It cannot be excluded that the inhibition 
of Wnt signaling by interfering with miR-135b and miR-889 levels is not potent enough to 
affect these processes.  
 
An intriguing question is what causes the aberrant expression of miRNAs as seen in MPNST. 
It was recently reported that in about 60% of NF1-derived MPNST the PRC2 complex is 
inactivated 44-46. The PRC2 complex is a well-known epigenetic modulator of gene expression 
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51 by establishing di-and trimethylation of histon H3 lysine 27 (HeK27me2 and HeK27me3) 
both critical epigenetic silencing marks. Inactivation of PRC2 leads to aberrant gene 
expression due to the loss of these silencing marks. A list of genes differentially expressed in 
MPNSTs with loss of PRC2 and those with wild-type PRC2 is presented by Lee et al. 45. 
Interestingly the expression of LEMD1, the gene that harbors miR-135b in one of its introns, 
is also induced upon PRC2 inactivation. This may explain the clearly increased levels of miR-
135b observed in at least some of the MPNST samples (Fig. 1, Supplementary Tables 4 and 
5) as it is co-expressed with its host gene LEMD1. Of note, the increased miR-135b levels may 
enhance Wnt signaling activity in the MPNST cells. Likewise, PRC2 inactivation may affect 
the miRNA cluster on chromosome 14 that contains four of the miRNAs, including miR-889, 
that were found upregulated in MPNST. However, PRC2 inactivation does not readily explain 
the downregulation of miRNAs observed in MPNST. Interesting in this respect are findings of 
de Raedt et al. who demonstrated that inactivation of PRC2 boosts the Ras signaling pathway 
which is already activated by the NF1 loss in these tumors 44. Ras activation has been reported 
to downregulate the expression of miR143/145 cluster 31 thereby explaining their relatively 
low levels in MPNST.  
 
Our findings indicate that miRNAs operate in a cell line specific manner as different NF1-
associated MPNST cell lines respond to miRNA modulation with different intensities or in a 
different fashion. It could be that the cell lines that comprise our MPNST cell line panel differ 
at a molecular level, perhaps reflecting different chromosomal copy number alterations as 
commonly observed in MPNST samples 52. This may cause the cell lines to respond differently 
to miRNA regulation. This is a highly relevant issue which is often overlooked, as usually only 
a limited number of cell lines is used in in vitro experiments to functionally characterize 
miRNAs. We have studied the cellular effects by modulating the levels of individual miRNAs 
transiently. It could very well be that miRNAs display additive, or even synergistic effects and 





From our study we conclude that at least some miRNAs play essential regulatory roles in 
MPNST facilitating tumor progression. These, and other miRNAs that are aberrantly expressed 
in MPNST, may be exploited as biomarker, with miRNA presence and/or levels being 
measured in suspect plexiform neurofibroma biopsies or in the circulation where they may 
signal the presence of MPNST. These avenues should be explored and can be particularly 
valuable in the context of neurofibromatosis type 1, with patients having a 10 – 13% life time 
risk of developing MPNST. Finally, as miRNAs are powerful regulatory biomolecules their 
therapeutic potential should be investigated in the context of MPNST in addition to the exact 
biochemical pathways and genes they regulate. These investigations may identify novel drug 
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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal malignancies 
found in the gastrointestinal tract. At a molecular level, most GISTs are characterized by gain-
of-function mutations in V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog 
(KIT) and Platelet Derived Growth Factor Receptor Alpha (PDGFRA) leading to constitutive 
activated signaling through these receptor tyrosine kinases, which drive GIST pathogenesis. 
In addition to surgery, treatment with the tyrosine kinase inhibitor imatinib forms the mainstay 
of GIST treatment particularly in the advanced setting. Nevertheless, the majority of GISTs 
develop imatinib resistance. Biomarkers that indicate metastasis, drug resistance and disease 
progression early on could be of great clinical value. Likewise, novel treatment strategies that 
overcome resistance mechanisms are equally needed. Non-coding RNAs, particularly 
microRNAs, can be employed as diagnostic, prognostic or predictive biomarker and have 
therapeutic potential. Here we review which non-coding RNAs are deregulated in GISTs, 
whether they can be linked to specific clinicopathological features and discuss how they 
can be used to improve the clinical management of GIST. 
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Gastrointestinal stromal tumors: a brief introduction 
 
Gastrointestinal stromal tumors (GISTs) are rare tumors of mesenchymal origin from the 
gastrointestinal (GI) tract with an estimated annual incidence of 10-20 per 1.000.000 in the 
population [1-3]. They can be found anywhere along the GI-tract, but occur most commonly 
in the stomach (60-70%) and small intestine (20-30%) [4]. GISTs are believed to originate 
from the interstitial cells of Cajal (ICC) or their precursor cells [5, 6]. In the GI-tract ICC 
operate as pacemaker cells responsible for peristaltic movement. That GIST originate from 
ICC is exemplified by shared immune-phenotypical features such as the expression of KIT 
(CD117) [5, 6], anoctamin 1 (ANO1 / DOG1) [7] and ETV1 [8] that are currently used a 
diagnostic biomarkers for GIST. Activating mutations in KIT or PDGFRA were identified as 
oncogenic drivers in GIST [9-11] (Figure 1A). The gain-of-function mutations in these 
receptor tyrosine kinases are mutually exclusive and cause constitutive kinase activity in the 
absence of growth factor binding. Activated KIT and PDGFRA signaling stimulate 
downstream pathways such as the RAS-RAF-MAPK, PI3K-AKT and JAK/STAT pathways 
inhibiting apoptosis and promoting cellular survival and proliferation [12] (Figure 1B). 
 
Figure 1. KIT receptor structure and KIT signaling. (A). The KIT proto-oncogene codes for a 145 kDa 
transmembrane receptor tyrosine kinase KIT (CD117). KIT, together with PDGFRA, belongs to the type 
III tyrosine kinase receptor family and consists of 5 extracellular immunoglobulin (Ig)-like domains 
involved in KIT ligand (Stem Cell Factor, SCF) binding, a transmembrane domain, a juxtamembrane 
region and an intracellular kinase domain. Mutations in GIST occur in exons that encode functional 
domains (arrows). (B). Constitutive KIT signaling as observed in GIST is transduced through the 
PI3K/AKT/mTOR, RAS-RAF-MAPK and JAK/STAT pathways thereby inhibiting apoptosis, promoting 




Approximately 80% of GISTs contain a mutation in KIT at specific locations in exon 11 (90%), 
exon 9 (8%) or - less often - in exon 13 (1%) or exon 17 (1%). KIT exon 11 encodes the 
juxtamembrane region, and mutations in this protein domain impair the autoinhibitory activity 
of the receptor. The mutations detected in exon 9 are supposed to imitate the conformational 
changes following ligand binding leading to receptor dimerization and activated signaling. 
Mutations in exon 13 act on the ATP-binding region of KIT while mutations in exon 17, which 
codes for the activation loop of the kinase, stabilize the receptor in its active conformation. 
PDGFRA mutations occur in 10-15% of GISTs, most commonly in exons 12, 14 or 18. The 
specific mutations in KIT and PDGFRA, with the exception of PDGFRA D842V, make GISTs 
amenable to treatment with the tyrosine kinase inhibitor imatinib. This drug selectively inhibits 
the kinase activity of KIT and PDGFR through competitive binding at the ATP binding site of 
these enzymes [13-15]. In a minority of GIST cases (5-10%) no mutations in KIT or PDGFRA 
can be detected. In these so-called wild-type GISTs (WT-GIST), other mutated genes like NF1, 
BRAF and succinate dehydrogenase subunits (SDHB, SDHC, SDHD) can drive tumorigenesis 
[16-20]. 
 
Current treatment of gastrointestinal stromal tumors 
 
Surgical excision is the preferred treatment modality for localized GIST aiming for resection 
margins devoid of tumor cells [21]. Prior to surgery, imatinib may be administered if complete 
resection is difficult without downsizing the tumor. If routine risk assessment, which is usually 
based on parameters like mitotic rate, tumor size and tumor location, indicates a significant 
chance of relapse after surgery adjuvant imatinib may be prescribed for up to 3 years [22]. The 
efficacy of imatinib treatment may vary and is partly dependent on the KIT or PDGFRA 
mutational status of the tumor [23]. For example, GISTs that harbor KIT exon 11 mutations 
generally respond well to imatinib [24, 25] whereas patients with an exon 9 KIT mutation 
frequently need an increased daily dose of 800 mg/day instead of the regular 400 mg/day to 
exhibit a treatment response [26]. Furthermore, PDGFRA D842V mutants are resistant to 
imatinib [27, 28], just like WT-GISTs and GISTs with mutations in genes other than KIT and 
PDGFRA that display insensitivity to imatinib and other tyrosine kinase inhibitors [29]. 
 
Imatinib is listed as first-line treatment for locally advanced, unresectable and metastatic GIST. 
In this context imatinib is usually prescribed indefinitely as treatment pausing generally leads 
to tumor progression [21]. Unfortunately, the vast majority of GIST patients treated with 
imatinib eventually presents with tumor progression due to the development of drug resistance 
[23]. The precise molecular changes and mechanisms underlying imatinib resistance are not 
completely clear. In about half of the patients, secondary mutations arise in KIT, normally in 
exon 13, 14, 17 or 18 that cause resistance [30-32]. In the remaining half of resistant patients 
other, less defined, resistance mechanisms are operational [30, 33-37]. Standard second-line 




Other tyrosine kinase inhibitors are under development of which avapritinib and ripretinib are 
the most promising and tested in phase III studies [41, 42]. These drugs were shown to have 
inhibitory activity in advanced GISTs resistant to approved treatments and in GISTs with a 
PDGFRA D842V mutation. 
 
Clinical needs regarding the management of 
gastrointestinal stromal tumors 
 
GIST is routinely diagnosed on specific morphological features, immunostaining for KIT and 
ANO1 (DOG1) and the presence of KIT or PDGFRA mutations. A risk assessment is being 
made by the pathologist based on the mitotic count observed in a tumor biopsy, the tumor size 
and tumor location. Additional biomarkers that can be quantitatively measured in a 
standardized fashion, may be very useful to further fine-tune the grading procedure. 
Additionally, one can think of biomarkers that highlight metastasis and can be determined in 
the patient’s tumor and/or circulation. Although effective treatments exist for GIST, most 
notably imatinib, almost all patient ultimately develop resistance. Biomarkers that indicate the 
development of resistance may not only provide insight into the specific mechanisms of 
resistance, leading to the development of novel strategies to overcome resistance, but also 
enable the clinician to adjust treatment before overt progression occurs. Last but not least, 
novel therapeutic approaches are needed that target the oncogenic pathways in GIST 





Novel classes of RNA transcripts, including microRNAs and long non-coding RNAs, have 
recently been discovered in eukaryotic cells. Their tissue specific expression, role in gene 
regulation and their intricate, often essential, involvement with normal- and pathological 
physiology makes them particularly suitable as biomarker and endows them with therapeutic 
potential.  
 
The sequencing of the human genome initially indicated the presence of approximately 
30.000 protein coding genes [43, 44], a number that over the years was adjusted to about 
20.500 protein coding genes [45]. GENCODE (www.gencodegenes.org) lists in its most recent 
version (release 34) 19.959 protein coding genes. This number of genes is comparable to that 
found in other – quite often less complex – organisms [46] implicating that organismal 
complexity is not determined by protein coding gene numbers alone. In fact, the protein coding 
genes constitute only 1.5% of the human genome but, intriguingly, about two-third of the 
genome is transcribed into RNA [47-49]. This vast transcriptional output cannot be all 
considered as transcriptional noise as that would be an utter waste of cellular energy. Based on 
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these facts it is proposed that organismal complexity is driven by the expansion of the 
regulatory potential of the non-coding portion of the genome [50]. There is growing evidence 
that non-coding transcripts exercise diverse biological functions that are still ill-defined or, 
more often, not yet assigned in most cases. Several classes of RNA transcripts have been 
recognized and a start has been made to functionally annotate these biomolecules. This review 
will focus on the rather well-defined subset of microRNAs (miRNAs), small regulatory RNAs 
of 19-26 nucleotides, and briefly touch upon long non coding RNAs (lncRNAs) and its 
subclass circular RNAs (circRNAs) in the context of GIST. MiRNAs were first described in 
the mid-nineties of the last century in the nematode Caenorhabditis elegans [51]. Initially 
miRNAs were considered a peculiarity of these worms until was realized that many miRNAs 
are evolutionarily conserved suggesting a functional relevance for miRNAs[52, 53]. Currently, 
there are 2654 mature human miRNAs listed in miRBase (version 22.1; 
http://www.mirbase.org/) and it is well established that miRNAs play pivotal roles by 
regulating many fundamental developmental and cellular processes [54]. Although exceptions 
have been reported [55, 56] miRNAs most commonly operate by binding in the context of the 
RNA induced silencing complex (RISC) to the 3’ untranslated region (3’ UTR) of target 
mRNAs. The miRNA-mRNA interaction in the context of RISC causes translation inhibition 
and/or mRNA degradation. In this way miRNAs are capable of regulating gene expression. 
Interestingly, any given miRNA may target multiple mRNAs and conversely a single mRNA 
can be targeted by multiple miRNAs. In this way a refined regulatory network is created which 
itself again can be modulated in various ways and at different levels. It is estimated that two 
third of all genes are under regulation by miRNAs [57, 58] by inference it is safe to state that 
miRNAs are small riboregulators involved in almost all – if not all – biochemical and cellular 
processes. Just as miRNAs are intimately related to normal cellular, tissue and organismal 
physiology they also play essential roles in diseases including cancer [59-61]. 
 
A common feature of cancer is the dysregulation of miRNA expression caused by the genomic 
alterations, amplification and deletions, that are frequently encountered [62]. Alternatively, 
epigenetic mechanisms may underlie the aberrant expression of miRNAs. It is well established 
that miRNAs can carry out essential oncogenic and tumor suppressive roles in the tumorigenic 
process. Additionally, miRNAs are also known to play a driving role metastasis [63] and drug 
resistance [64] thereby affecting the outcome of drug treatment. The close involvement of 
miRNAs with many biological and clinical aspects of cancer, their tissue-specific expression 
and quantitative detection methods defines miRNAs as suitable biomarkers. Advantageous in 
this respect is that miRNAs are stable present in many tissues and body fluids such as urine, 
saliva and blood [65, 66]. Driven by academic progress that highlights the key roles miRNAs 
play in all kinds of disorders, the pharmaceutical industry and biotech developed an interest in 
miRNA-based therapeutics. Despite significant initial technical challenges related to safety, 
stability and delivery numerous clinical trials are ongoing [67, 68].  
 
Recently other classes of RNA transcripts such as long non-coding RNAs (lncRNAs) and 
circular RNAs (circRNAs) gained a lot of attention. LncRNAs are broadly defined as 
transcripts > 200 nucleotides in length that are transcribed from independent pol II promoters 
and not translated into protein. LncRNAs comprise a rather heterogeneous class of transcripts 
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that includes intergenic and intronic transcripts, enhancer RNAs, pseudogenes, circular RNAs 
(circRNAs) and sense and antisense transcripts that overlap with other genes. Currently 
GENCODE v34 annotates 48.479 lncRNA transcripts from 17.960 lncRNA genes. LncRNA 
genes can consist of multiple exons, that upon transcription are subjected to regular splicing 
resulting in transcripts that contain a 5’CAP structure and 3’poly (A) tail. The majority of 
lncRNAs are not highly conserved between species and many lncRNAs display a lineage 
and/or cancer specific expression [69]. LncRNAs are found capable of regulating gene 
expression by diverse mechanisms operating at epigenetic, transcriptional or post-
transcriptional levels [68, 70-73]. They either function in cis, mediating effects nearby, or in 
trans at distant genomic or cellular locations. LncRNA have been reported to direct chromatin 
modifying complexes to specific gene promoters, to bind transcription factors or RNA binding 
proteins, often involved in creating scaffolds facilitating interactions between different 
biomolecules. They are also known to bind directly to DNA or function as competitive 
endogeneous RNA (ceRNA) acting as miRNA sponges. Some lncRNAs have been 
functionally characterized as essential actors in tumorigenesis and tumor maintenance either 
in oncogenic or tumor suppressive roles [68, 74, 75]. However, the relevance and precise 
functions of the vast majority of lncRNAs and their integration in normal or diseased states 
remains to be elucidated.  
 
Although the presence of circRNAs was already reported a few decades ago, a publication by 
Salzman et al. in 2012 renewed the interest in these transcripts by emphasizing their abundance 
and variety of in mammalian cells [76]. CircRNAs are single-stranded, covalently closed 
circular RNA molecules produced by precursor mRNA back-splicing of exons in which a 
downstream 5’splice site is linked with an upstream 3’splice site [77]. The process of back-
splicing is facilitated the canonical spliceosomal machinery and regulated by complementary 
sequences in introns flanking the circularized exons and RNA binding proteins [78]. It appears 
circRNAs are found throughout the eukaryotic kingdom and are usually expressed in lineage 
specific patterns. Their circular nature endows them with increased stability providing a 
distinct advantage for use as biomarker. Initially considered the results of aberrant splicing it 
is now recognized that at least some circRNAs fulfil important biological functions [78]. 
However, so far only few circRNAs have been functionally characterized, a process that is 
hampered by technical hurdles as circRNAs resemble their linear counterparts [78]. CircRNAs 
have been implicated in carcinogenesis. Using an exome capture RNA sequencing protocol a 
comprehensive catalogue (MiOncoCirc) was generated of circRNAs detected in more than 
2000 cancer samples derived from >40 cancer sites and included primary and metastatic 
tumors as well as rare tumor types [79]. MiOncoCirc lists >125.000 species of cancer-related 
circRNAs. In general, it is believed that circRNAs can function as ceRNAs capable of 
sequestering miRNAs and/or RNA binding proteins [68]. Future research will shed more light 
on the functional significance of circRNAs in physiological and pathological circumstances 






Dysregulated miRNAs in GIST 
 
Several research groups examined which miRNAs are aberrantly expressed in GIST as a first 
step in identifying miRNAs essential for the tumorigenesis, maintenance and progression of 
GIST (see Table 1 for an overview). Subramanian et al. discovered, analyzing the miRNA 
expression profiles in various sarcomas, that each sarcoma subtype, including GIST, was 
characterized by its own unique miRNA expression signature [80]. In addition to KIT or 
PDGFRA mutations, GIST displays characteristic genomic alterations most notably a loss of 
the long arm of chromosome 14 [81] and deletions of chromosome 1p and 22q [82, 83]. Loss 
of chromosome 14q is seen in approximately 70% of GISTs. Interestingly, Choi et al. reported 
on the existence of miRNA expression patterns linked to 14q loss. Many miRNAs that are 
actually located on chromosome 14q appear downregulated [84]. Haller et al. described 
localization and mutation dependent miRNA expressions patterns in GIST focusing on miR-
132, miR-221, miR-222 and miR-504 [85]. Particular attention, by several research groups, 
has been given to miR-221/222 as these miRNAs were reported to regulate KIT receptor 
expression [86]. It was shown that miR-221/222 were downregulated in GIST and correlated 
to KIT expression [87] and also in GIST cells target KIT [88, 89]. Enhanced expression of 
miR-222 in GIST cells by miRNA mimics inhibited cell proliferation, affected cell cycle 
progression and induced apoptosis [88]. Also, miR-218 and miR-375-3p were mentioned to 
regulate KIT as well as miR-494, a miRNA associated with 14q loss [90-92]. Transient 
modulation of miR-494 in the GIST882 cell line led to inverse responses in KIT protein levels. 
Moreover, miR-494 overexpression provoked apoptosis, impaired cellular proliferation and 
affected the cell cycle. Interestingly, in a subsequent paper the research group reported that 
miR-494 also targets survivin (BIRC5) [93]. These findings led the authors to propose that 
miR-494 synergistically suppresses GIST when expressed by targeting both survivin and KIT. 
These KIT targeting miRNAs as well as the ETV1 targeting miR-17 and miR-20a [88] may be 
of therapeutic value particularly in drug resistant disease in which GISTs still rely on KIT 
signaling. Yamamoto et al. noted that miR-133b was among downregulated miRNAs in high-
grade GIST compared to intermediate and low-grade GISTs and further demonstrated that 
fascin-1 (FSCN1) expression was regulated by miR-133b [94]. It was subsequently shown that 
overexpression of FSCN1 correlated to shorter disease-free survival time and aggressive 
pathological factors. Tong et al. reported miRNA expression profiles that distinguish between 
malignant and more benign GISTs and between malignant and borderline GISTs [95]. 
Comparing GISTs with leiomyomas Fujita et al. described the upregulation of miR-140 in the 
GIST samples [96] but do not indicate potential mRNA targets. The epigenetic silencing of 
miRNAs in GIST was investigated by Isosaka et al. [97]. An in vitro screen using the cell line 
GIST-T1 revealed at least 21 miRNAs whose expression was associated with the methylation 
of an upstream CpG-island. MiR-34a and miR-335, miRNAs found silenced in GIST were 
further functionally characterized and were shown to suppress cellular proliferation of GIST-
T1 cells when overexpressed. In addition, miR-34a, but not miR-335, affected migratory and 
invasive processes and was demonstrated to regulate PDGFRA. Using novel high-throughput 
sequencing methods Gyvyte et al. uncovered and validated miRNAs deregulated in GIST in 
comparison to adjacent normal tissue [98]. It was found that miR-215-5p levels were 
negatively correlated with the risk-grade of GIST and that miR-509-3p is upregulated in 
epitheloid and mixed cell type GIST compared to the spindle type. In a subsequent study the 
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same group focused on miR-200b-3p and miR-375-3p, both found reduced in GIST compared 
to normal adjacent tissue [91]. These miRNAs negatively affected cell viability and cellular 
migratory capability when overexpressed in GIST-T1 cells. MiR-200b-3p was demonstrated 
to directly target EGFR and indirectly affected ETV1 protein levels whereas miR-375-3p 
targeted KIT. A cell line study by Lu et al. revealed that miR-152 is downregulated in GIST 
cells, its overexpression inhibited tumor cell proliferation and induced apoptosis [99]. 
Interestingly, the miR-152 phenotype is mediated through the regulation of cathepsin L 
(CTSL). In search of new miRNA-based treatments for GIST Long et al. identified the 
overexpression of miR-374b in GIST and provided evidence that this miRNA targets the tumor 
suppressor PTEN [100]. It is suggested that miR-374b enhances survival, migration and 
invasion and inhibits apoptosis by stimulating the PI3K/AKT signaling pathway through 
downregulation of PTEN. The authors tentatively conclude that inhibition of miR-374b 
constitutes a novel therapeutic strategy for GIST. A different group highlighted that miR-4510 
downregulation, as normally is observed in GIST cells, promotes GIST progression including 
tumor growth, invasion and metastasis through the increase of apolipoprotein C-II (APOC2) 
shown to be a miR-4510 target [101].  
 
Some studies investigated both mutant GISTs and WT GISTs describing differentially 
expressed miRNAs between these GIST subtypes [102, 103]. Bioinformatic analyses led 
Pantaleo et al. to propose the existence of mRNA/miRNA regulatory networks that may be 
therapeutically targeted in WT GIST [103]. Bachet and co-workers examined miRNA 
expression profiles in murine NIH3T3 cells expressing either human wild-type KIT, 
hemizygous KIT mutants del 557-558 (D6) or del 564-581 (D54), heterozygous KIT mutants 
wild-type/D6 or wild-type/D54 and, for validation purposes, in human GIST samples [104]. 
Importantly, the authors concluded that miRNA, as well as mRNA, expression profiles depend 
on the homozygous/heterozygous/hemizygous status of the KIT mutations and the 
deletion/presence of TYR568 and TYR570 residues. These results appear to suggest different 
oncogenic pathways are activated and should be further validated using well-characterized 
GIST samples.  
 
The various screens comparing tumor tissue with adjacent non-cancerous tissue usually 
indicate many miRNAs that are deregulated in GIST. However, it is often not clear which of 
the listed miRNAs fulfil a key oncogenic or tumor suppressive role in cancer-related processes 
and which miRNAs are not. In-depth, and often time-consuming, functional studies are 
necessary that first should establish which miRNAs affect cancer-related processes when 
modulated. Ideally these experiments should be performed both in vitro using well-
characterized cell lines and in relevant in vivo models. Once a miRNA is singled out in this 
way its target genes and pathways should be identified in the GIST context. To this end 
bioinformatics may be used as well as unbiased biochemical approaches e.g. PAR-CLIP [105]. 
Once a miRNA target has been defined and validated it is important to verify that modulation 
of the target(s) e.g. by RNAi and/or overexpression experiments phenocopies the miRNA 
related cellular phenotype. The findings should be linked to the situation seen in the clinic so 
some sort of validation using clinical samples is needed to corroborate the clinical relevance. 
In this respect much work still needs to be done.  
 
 85 




























tumor and tissue 
samples 
Primary GIST 




































14q loss (n=14) 
vs 14q presence 
(n=6) 
Microarray  Association with 14q 
loss 
[84] 










miR-132; miR-221; miR-222; miR-
504 
 High miR-132 
expression level 
associated with gastric 
PDGFRA-mutated GIST 
cf. gastric KIT-mutated 
GIST 
 High miR-221 and miR-
222 expression levels 
associated with wild-
type GIST cf. GIST with 





 High miR-504 
expression associated 
with gastric GIST with 
KIT mutation cf. 


















 miR-494; KIT 





















miR-17, miR-20a; ETV1 
miR-222; KIT 
[88] 




(n=30) vs adult 
WT GIST (n=25) 
vs pediatric WT 
GIST (n=18) 
RT-PCR  Distinct miRNA 





























3p; miR-330-3p; miR-455-5p; miR-
129-1-3p; miR-129-2-3p; miR-876-
5p 
 miR-139-5p and miR-
455-5p predicted to 
target IGF1R 
 miR-139-5p predicted to 
target CDK6 














miR-133b; inverse correlation 
between fascin-1 and miR-133b 










tissue (n=5)  
























(n=24) vs smooth 
muscle (n=6) 















RT-PCR miR-34a, PDGFRA 
miR-335 













GIST (n=30) vs 
benign GIST 
(n=9)b 
















GIST (n=30) vs 
borderline GIST 
(n=14)b 































All listed miRNAs validated 
 miR-215-5p expression 
levels are negatively 
correlated to risk grade 
 miR-509-3p expression 
















Pairs (n=143) of 
Primary GIST and 
adjacent tissue  
RT-PCR miR-374b; PTEN 
 Association of miR-































 Association of miR-
4510 levels with tumor 
location, tumor size, 





















a In case multiple miRNAs have been detected only the 10 most significant differentially expressed 
miRNAs are listed / or miRNAs with the highest fold-change /or miRNAs of which de deregulation is 
validated. 
b Classification into benign, borderline and malignant GIST according to [106, 107]  
c The miRNAs listed in bold were detected in two of more independent studies. 
Abbreviations: FFPE, formalin-fixed paraffin-embedded; SS, synovial sarcoma; LMS, leiomyosarcoma; 
DDLPS, dedifferentiated liposarcoma; RMS, rhabdomyosarcoma; NSM, normal smooth muscle. 
 
 
MiRNAs associated with Gastrointestinal Stromal 
Tumor metastasis 
 
When GIST metastasizes, treatment becomes more difficult as complete surgical resection is 
not an option anymore. Biomarkers that indicate whether metastasis is about to occur or has 
already occurred are therefore useful. A limited number and/or small metastatic lesions may 
be more susceptible to systemic treatment. Several researchers identified miRNAs present in 
tumors of which the expression levels are associated with metastasis (Table 2). At least 27 
miRNAs were found downregulated in high-risk GISTs when 10 high-risk GISTs were 
compared to 4 low-risk tumors [84]. Niinuma et al. identified miR-196a as being positively 
correlated with high-risk grade GIST but also with poor clinical outcome, tumor size, mitotic 
count and metastasis [108]. MiR-196a is known to be expressed from the HOX gene clusters 
in mammals. Intriguingly, HOXC and the lncRNA HOTAIR were coordinately expressed with 
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miR-196a. MiR-196a inhibition, however, did not affect HOTAIR levels and conversely 
knockdown of HOTAIR had no effect on miR-196a levels, the authors suggest an epigenetic 
mechanism underlies the linked expression. In a later paper the same group demonstrated that 
downregulation of miR-186 was observed in tumors that exhibit metastatic recurrence. 
Analysis of a large validation cohort of 100 primary GISTs uncovered that miR-186 expression 
is correlated to metastatic recurrence and poor prognosis. It was further shown that inhibition 
of miR-186 in a GIST cell line promoted cell migration, most likely by upregulation of multiple 
genes implicated in cancer metastasis [109]. Akçakaya et al. identified 44 miRNAs that could 
distinguish between metastatic and non-metastatic tumors with 19 overexpressed and 25 
underexpressed in metastatic GISTs [110]. Unfortunately, none of these miRNAs were further 
functionally characterized. MiR-137, a miRNA found downregulated in GIST, was reported 
to modulate epithelial-mesenchymal transition (EMT) in GIST. Follow-up experiments 
involving GIST cell lines indicated that miR-137 expression enhanced epithelial cell 
morphology, possibly by reducing TWIST1 levels. Increased miR-137 levels led to reduced 
cell migration, activated a G1 cell cycle arrest and induced apoptosis [111]. Similarly, Ding et 
al. revealed that miR-30c-1-3p, miR-200b-3p and miR-363-3p may modulate EMT and hence 
invasiveness and consequently metastasis by regulation of SNAI2, a member of the snail C2H2-
type zinc finger transcription factor family [112].  
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 [110] 
a In case >10 miRNAs were identified only the 10 miRNAs with the most significant expression or highest 
fold-changes are listed. 




MiRNAs related to imatinib resistance 
 
Imatinib has been a truly groundbreaking drug for the majority of GIST patients prolonging 
overall survival and quality of life [113]. Unfortunately, most GIST patients eventually 
become insensitive to imatinib and present with a tumor that is progressing and requiring other 
treatments. Several groups have investigated whether miRNAs can be linked to imatinib 
resistance (Table 3). These miRNAs can either be used as biomarker signaling drug resistance 
and possibly tumor progression or alternatively be exploited to obtain insight into the 
molecular mechanisms of resistance. Goa et al. compared the miRNA expression profiles of 
primary – imatinib naïve – and imatinib resistant GIST. MiR-320a, downregulated in imatinib-
resistant GIST, was found associated with imatinib resistance although its mode of operation 
is not further investigated [114]. A cell line study by Fan et al. described that miR-218 is 
downregulated in resistant GIST contributing to the phenomenon of resistance by regulating 
PI3K/AKT signaling [115]. Akçakaya and coworkers, direct attention to the upregulation of 
miR-107, miR-125a-5p, miR-134, miR-301a-3p and miR-365 in association with imatinib 
resistance. A single miRNA, miR-125a-5p, is functionally characterized and shown to regulate 
PTPN18 and consequently pFAK levels [110, 116]. Zhang et al. performed an in silico 
analyses, using GO function and KEGG pathway enrichment as well as lncRNA-miRNA-
target gene regulatory network build, of the microarray datasets deposited by Akçakaya et al 
[110]. These studies highlighted miR-28-5p and – not surprisingly – miR-125a-5p both of 
which displayed a significant correlation to imatinib resistance and imatinib sensitivity [117]. 
Also, Shi et al. uncovered a series of up- or downregulated miRNAs by comparing imatinib-
naïve with imatinib-resistant GIST samples [118]. A single miRNA, miR-518a-5p 
downregulated in imatinib resistant GIST, was further investigated and demonstrated to bind 
to the 3’UTR of PIK3C2A. It is proposed that the increased PIK3C2A expression affects the 
cellular response to imatinib and causes resistance. Kou et al. examined the miRNA expression 
profiles of serum samples derived from GIST patients having an imatinib responsive tumor or 
a tumor that progresses on the drug [119]. Receiver operating characteristics (ROC) curves 
demonstrated that miR-518e-5p levels could discriminate serum samples of imatinib-resistant 
GIST patients from imatinib-sensitive ones with high sensitivity (99.8%) and specificity 
(82.1%). Thirty-five differentially expressed miRNAs were detected comparing primary, 
imatinib-naïve and imatinib-resistant GISTs [30]. An accompanying mRNA profiling of a 
smaller subset of the same samples uncovered 352 differentially expressed mRNAs, 
subsequent pathway and network analyses implicated cell cycle and cell proliferation genes as 
involved in imatinib resistance.  
 
It is noted that the observed differences in miRNA expression between imatinib sensitive and 
resistant GIST tumors are relatively small. Nevertheless, even small miRNA differences may 
still have a significant impact as diverse miRNAs may act synergistically and the regulation of 
multiple targets within the same pathway may amplify biological effects [120, 121]. Despite a 
comparable set-up there is little overlap in imatinib-resistance linked miRNAs between the 
different studies. Of interest in this respect are miR-518a-5p, miR-518e-5p and miR-518d-5p 
that all derive from a large cluster of miRNAs on chromosome 19q13.42 a chromosomal region 
that may function in imatinib resistance. However, more extensive research is needed, 
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investigating the expression of other miRNA cluster members as well as chromosomal 
alterations that affect chromosome 19q.  
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a In case multiple miRNAs have been detected only the 10 most significant differentially expressed 
miRNAs are listed. 
b miRNA expression data used are from public repository described in Akçakaya et al. (2014) [110] 
 
 
Additional non-coding RNAs in Gastrointestinal 
Stromal Tumors 
 
Recently the association of lncRNAs with GIST and GIST pathological features was 
investigated (see Table 4 for an overview). In 2012, Niinuma and coworkers observed that the 
lncRNA HOTAIR expression was associated with high-risk grade GIST, metastasis and poor 
clinical outcome [108]. RNAi mediated knockdown of HOTAIR was shown to inhibit 
invasiveness, a surrogate for metastatic potential, of the GIST-T1 cell line. Basically, these 
findings were confirmed and expanded by others [122, 123]. Lee et al. demonstrated that 
HOTAIR in GIST cells suppressed apoptosis, was associated with cell cycle progression and 
controlled both invasion and migration [123]. Evidence is presented that HOTAIR through 
binding of PRC2 complex components, an epigenetic regulator of gene expression [124], 
affects the expression of distinct proteins, like protocadherin 10 (PCDH10), thereby mediating 
the HOTAIR phenotype. Bure et al. observed that HOTAIR depletion resulted in aberrant 
DNA methylation patterns through an unknown mechanism, causing either hypo- or 
hypermethylation patterns that affect gene expression [122]. Hu et al. reported a relative high 
expression of amine oxidase copper containing 4, pseudogene (AOC4P) in high-risk GIST and 
noted that also the epithelial-mesenchymal transition (EMT) related proteins ZEB1, SNAIL 
and Vimentin were highly expressed [125]. Knockdown of AOC4P affected the migratory and 
invasive capabilities of GIST cells, induced apoptosis and reduced EMT. Two reports 
examined the lncRNA CCDC26 in GIST indicating its link with imatinib-resistance through 
interacting with KIT and IGF-1R proteins [126, 127]. Badalamenti et al. investigated the 
expression levels of the well-known lncRNAs H19 and MALAT1 in GIST. MALAT1 
expression appeared to be associated with KIT mutation status. Interestingly, H19 and 
MALAT1 expression was significantly higher in patients that respond poorly to imatinib i.e. a 
time-to-progression of < 6 months that perhaps indicates intrinsic resistance [128]. It is 
concluded that both H19 and MALAT1 expression levels hold prognostic potential to stratify 
GIST patients for first-line treatment with imatinib with high expressors indicating poor 
response to imatinib. H19 was also detected to be upregulated – together with FENDRR – in 
GIST samples compared to adjacent normal tissue by Gyvyte et al. [129]. The expression of 
multiple lncRNAs was analyzed by Yan et al. using a commercially available platform capable 
of detecting 63.542 lncRNAs and 27.134 mRNAs [130]. Most interestingly, differentially 
expressed lncRNA and mRNAs between primary GIST and imatinib-resistant GIST were 
identified. Further, in silico pathway- and network analyses implicated the hypoxia-inducible 
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factor 1 pathway as a mediator of imatinib resistance. The role of the lncRNA prostate cancer 
associated transcript 6 (PCAT6) was examined by Bai et al. [131]. First, PCAT6 was found to 
be upregulated in GIST in comparison with adjacent non-cancerous tissue. Follow-up in vitro 
studies revealed PCAT6 facilitated cancer by repressing apoptosis, enhancing cellular 
proliferation and – notably - by increasing GIST cell stemness and activating Wnt/β-catenin 
signaling. Further experiments showed miR-143-3p is a tumor suppressive miRNA in GIST 
as its expression levels are reduced in GIST cell lines in comparison to ICC. An RNA pull-
down assay using biotinylated PCAT6 provided evidence that miR-143-3p is sequestered by 
PCAT6 causing the miR-143-3p target gene peroxiredoxin 5 (PRDX5) to be upregulated. 
Rescue experiments revealed that PCAT6 regulates GIST cell proliferation, apoptosis and 
stemness by reducing miR-143-3p and enhancing PRDX5. 
 
CircRNAs are a recently recognized class of cellular transcripts that potentially have the 
capability to affect cellular processes and contribute to pathological processes including cancer 
[132]. A first study was performed by Jia and co-workers who used ceRNA microarrays that 
can monitor the expression of 88,371 circRNAs and 18.853 mRNAs [133]. When comparing 
3 pairs of GIST and normal adjacent tissue a total of 5770 differentially expressed circRNAs 
and 1815 mRNAs were detected. Three circRNAs (circ_0069765; circ_0084097; 
circ_0079471) that localized to the host genes KIT, PLAT and ETV1 and were upregulated in 
GIST were further investigated. The circRNAs contained 3 – 6 exons of their host genes and 
their upregulation was confirmed by RT-PCR in a relatively large validation cohort (n= 68). 
Next, miRNAs predicted to bind to the circRNAs were identified and a circRNA-miRNA-
mRNA regulatory network was created. From these studies the authors concluded that the 
circRNAs, host genes and miR-142-5p, miR-144-3p and miR-485-3p may be key regulators 
in GIST. 
 
Table 4. Long non-coding RNAs in gastrointestinal stromal tumors. 
Lnc RNA Up/Down regulation Functional role Ref. 
HOTAIR Upregulation in high-risk 
GIST cf. low and intermediate 
GIST 
 Repression apoptosis 
 Stimulation invasion and 
migration  
 Stimulation cell proliferation 
 Hypo- and hypermethylation 





AOC4P Upregulation in high-risk 
GIST cf. low and intermediate 
GIST 
 Repression apoptosis 
 Stimulation invasion and 
migration  
 Induction EMT 
[125] 
CCDC26 Low expression linked to 
imatinib resistance 
 CCDC26 interacts with c-KIT 
and IGF-1R 
 CCDC26 knockdown 
upregulate c-KIT and IGF-1R 
[126, 
127] 
FENDRR, H19 Upregulation in GIST cf. 
adjacent normal tissue 
 Positive correlation between 




 Positive correlation between 
H19 and miR-455-3p 
H19 High expression in advanced 
GIST with TTP<6 months 
 [128] 
MALAT1 High expression in advanced 
GIST with TTP<6 months 




















Downregulation in imatinib 
resistant GIST 
 HIF1 pathway regulation [130] 
PCAT6 Upregulation in GIST cf. 
adjacent normal tissue 
 Repression apoptosis 
 Stimulation cell proliferation 
 Promotion GIST stemness 
 Activation Wnt/β-catenin 
signalling 





Upregulation in GIST cf. 
adjacent normal tissue 
 Role in predicted network of 
circRNAs, host genes (KIT, 
PLAT, ETV1, resp.) and miR-
142-5p, miR-144-3p and 485-
3p.  
[133] 





It is evident that non-coding RNAs can be exploited as diagnostic, prognostic and predictive 
biomarkers. The investigations carried out with GIST report diagnostic miRNA classifiers that 
distinguish GIST from other sarcomas [80, 88, 134], identify histological and molecular 
subtypes [85, 98] and define location specific markers [85]. Of particular clinical interest are 
the miRNAs associated with relapse risk [84, 94, 95, 98, 101, 108-110, 112, 135] that may be 
used to predict tumor recurrence and metastasis. These prognostic biomarkers may be further 
developed into a more quantitative risk evaluation for GIST which is now based on mitotic 
index, tumor size and tumor location. Finally, miRNAs associated with imatinib resistance 
[30, 110, 114, 115, 117-119] may be used to signal evolving imatinib resistance enabling early 
clinical intervention. Interestingly, also lncRNAs have been identified that could be used for 
diagnostic purposes [129, 131, 133] or are specifically linked to high-risk / advanced GIST 
[108, 122, 123, 125, 128] and imatinib resistance [126, 127, 130]. However, more research is 
necessary to select the miRNA classifiers that are most promising for validation in prospective 
clinical studies. Most studies so far provide proof-of-principle that biomarkers can be 
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identified but do so on a limited number of samples (Table 1). To end up with reliable 
biomarkers, future studies should avoid caveats and be aware of the critical steps in miRNA 
related translational research [136-138]. First, appropriately sized sample cohorts should be 
analyzed taking tumor heterogeneity into account. In addition, the tumor samples must be well-
characterized, preferably come from different laboratories and meet certain defined and 
stringent quality criteria. Ideally, an unbiased, robust and reliable screening procedure should 
be used that can be standardized and easily executed in different laboratories. For miRNAs 
one could consider an RNA-seq approach adapted to suit the class of small RNAs one is 
interested in. The data should be analyzed using appropriate statistics and the biomarkers 
should display a defined sensitivity and specificity. It can very well be that a robust classifier 
needs to be based on the expression of an miRNA panel. For relatively rare tumors such as 
GIST- but also for more abundant tumor types - it unavoidable to carry out these studies in 
international consortia particularly if one intends to bring biomarkers to the clinic [139].  
 
The majority of biomarkers studies on GIST were carried out using tumor samples acquired 
by invasive biopsies or after tumor resection (Tables 1, 3). The exploitation of liquid biopsies, 
often simple blood draws in a minimally invasive way, have not yet been extensively 
investigated in GIST patients. Only few investigators examined the miRNA profiles in serum 
samples. Distinct serum miRNA expression patterns were observed between GIST patients 
and healthy controls [134] and miR-518e-5p was identified a classifier for imatinib resistance 
[119]. Circulating miRNAs or other non-coding RNAs - either packaged in extracellular 
vesicles or not - may signal tumor recurrence, development of drug resistance and tumor 
progression or indicate metastasis. Particularly, frequent sampling in high-risk patients may 
indicate disease progression early on, enabling early clinical intervention. 
 
Therapeutic potential of non-coding RNAs 
 
The mere fact that non-coding RNAs play key roles in carcinogenesis, displaying either 
oncogenic or tumor suppressive functions, and cancer progression implies they have 
therapeutic potential. This has also been demonstrated in various laboratories for GIST. Of 
interest in this respect are the miRNAs that target the KIT receptor: miR-218 [90], miR-
221/222 [88, 89] and miR-494 [84, 92]. Alternative targets with therapeutic potential are 
PDGFRA, reported to be targeted by miR-34a [97], PTEN [100], BIRC5 [93] and APOC2 
[101]. Also amenable for therapeutic modulation are the lncRNAs HOTAIR [108, 122, 123], 
AOC4P [125] and PCAT6 [131]. In principle, one could restore expression of non-coding 
RNAs that display reduced levels in cancer using mimics. Conversely, overexpressed non-
coding RNAs may be inhibited using antisense approaches. RNA targeting therapeutic 
approaches have been discussed in the literature since the discovery of RNAi in the nineties 
but encountered significant challenges related to stability, delivery, importantly tissue 
specificity, tissue penetrance and intracellular trafficking, and toxicities [140, 141]. Although 
many of these issues have not been completely solved significant advances have been made as 
exemplified by FDA approved oligonucleotide drugs aimed to induce cleavage of a target 
mRNA or alter the splicing pattern [142]. RNA oligonucleotides are chemically modified to 
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increase stability, providing protection against nucleases, and improve target binding affinity 
[143, 144]. Most importantly, the use of 2’-O-methy substitutions in the sugar backbone of the 
RNA, 2’-fluoro- or locked nucleic acid (LNA) bases and the use of oligoribonucleotides with 
phosphorothioate linkages replacing the regular phosphodiester bonds [145]. Moreover, 
oligonucleotides with a peptide backbone have been generated giving rise to increased stability 
and binding affinities, additional modifications e.g. cholesterol conjugation and cell 
penetrating peptides may improve cell uptake. Currently nanoparticles, notably lipid-based 
nanocarriers and polymer-and peptide particles are being generated. The packaging of 
oligoribonucleotides in nanoparticles partly overcomes the stability issue and allows for 
innovative ways to direct the particles to the target tissue [145]. Particularly the progress made 
in delivery technologies have enabled clinical trials in which non-coding RNA-based 
therapeutic agents are tested in patients [67, 68]. Finally, as the functional significance of the 
vast majority non-coding RNAs, especially lncRNAs in specific cancers, remains unknown it 
is virtually impossible to select the best candidate for therapeutic intervention. This problem 
may be solved by the use of large-scale CRISPR-CAS9 based screens to rapidly determine the 




With the ongoing functional annotation of the non-coding genome comes the realization that 
non-coding transcripts constitute a central and essential element of eukaryotic biology and as 
such are intimately involved in all kinds of pathological processes including cancer. The 
clinical relevance of non-coding RNAs is emphasized by many studies listed in the clinical 
trial database (http://clinicaltrials.gov) that evaluate non-coding RNAs. Frequently these trails 
concern oncological patients in which non-coding RNA expression levels are determined and 
linked to clinicopathological data for biomarker purposes [68]. 
 
For GIST, non-coding RNA biomarkers associated with high-risk GISTs and imatinib 
resistance may be particularly relevant and obtain a place in the clinical management of this 
disease. As current biomarker discovery studies are based on relatively small sample cohorts 
additional research is required to validate the found biomarker signatures. At the same time 
the specificity and sensitivity of the biomarker signatures should be determined and how they 
relate to the traditional clinical and pathological classifiers. 
 
In current clinical practice advanced GISTs are being effectively treated with imatinib and 
other small molecule inhibitors targeting the receptor tyrosine kinases KIT and PDGFRA. It 
seems that for GIST therapeutic targeting of key non-coding RNAs is less relevant. However, 
eventually all patients develop (multi)drug resistance yielding the GISTs unresponsive to 
drugs. In this instance additional drug targets are needed that, when inhibited or stimulated, 
affect the ongoing signaling through KIT or PDGFRA. signaling. MiRNA or lncRNAs based 
therapeutic approaches can be of use in this setting. Challenges, however, remain and mainly 
involve drug safety and targeted delivery issues [142]. Nevertheless, the future will see the 
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enormous potential of the noncoding genome unleashed revealing new biology followed – 
undoubtedly - by clinical applications in the form of specific and sensitive biomarkers or the 
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Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 
50% of the patients experience resistance within two years of treatment underscoring the need 
to get better insight into the mechanisms conferring imatinib resistance. Here the microRNA 
and mRNA expression profiles in primary (imatinib-naïve) and imatinib-resistant GIST were 
examined. Fifty-three GIST samples harboring primary KIT mutations (exon 9; n = 11/exon 
11; n = 41/exon 17; n = 1) and comprising imatinib-naïve (IM-n) (n = 33) and imatinib-resistant 
(IM-r) (n = 20) tumors, were analyzed. The microRNA expression profiles were determined 
and from a subset (IM-n, n = 14; IM-r, n = 15) the mRNA expression profile was established. 
Ingenuity pathway analyses were used to unravel biochemical pathways and gene networks in 
IM-r GIST. Thirty-five differentially expressed miRNAs between IM-n and IM-r GIST 
samples were identified. Additionally, miRNAs distinguished IM-r samples with and without 
secondary KIT mutations. Furthermore 352 aberrantly expressed genes were found in IM-r 
samples. Pathway and network analyses revealed an association of differentially expressed 
genes with cell cycle progression and cellular proliferation, thereby implicating genes and 
pathways involved in imatinib resistance in GIST. Differentially expressed miRNAs and 
mRNAs between IM-n and IM-r GIST were identified. Bioinformatic analyses provided 
insight into the genes and biochemical pathways involved in imatinib-resistance and 







Gastrointestinal stromal tumors (GISTs) are rare mesenchymal malignancies associated with 
the gastrointestinal tract that originate from the interstitial cells of Cajal (ICC) or precursors 
thereof [1]. GISTs and ICC share morphological and immunophenotypic features, notably the 
expression of KIT and CD34. Molecularly, GISTs are characterized by the presence of 
oncogenic gain-of-function mutations in KIT (~80% of cases) or PDGFRA (~10% of cases) 
[2,3]. KIT and PDGFRA mutations are absent in the so-called wild-type GISTs (~10% of cases) 
that may contain mutations in BRAF, NF1, or defects of the succinate dehydrogenase (SDH) 
complex [4]. The constitutive activation of KIT and PDFGRA signaling in the majority of 
GISTs drives tumor growth through the activation of downstream signaling cascades such as 
the RAS–RAF–MAPK, PI3K–AKT, and STAT3 pathways facilitating cell proliferation and 
survival [5]. The advent of the tyrosine kinase inhibitor imatinib mesylate, which targets both 
KIT and PDGFRA, has dramatically improved the outcome of patients with advanced disease 
[6,7]. Despite this great progress in GIST treatment and the fact that approximately 10% of the 
patients benefit for more than 10 years from imatinib [8], the majority of patients eventually 
develop imatinib resistance (acquired resistance) [8] with about 10% of GIST patients 
experiencing progression already within 6 months of start of therapy (intrinsic resistance) 
[6,7]. Where in intrinsic resistant cases in particular KIT exon 9 mutations or PDGFRA D842V 
mutations are involved [9], acquired resistance may occur because of secondary mutations 
within KIT that interfere with the binding of imatinib [10–14]. These resistance-causing 
secondary mutations cluster in two regions: (i) ATP-binding pocket (encoded by exons 13 and 
14), and (ii) kinase catalytic regions/activation loop (encoded by exons 17 and 18). Such 
secondary mutations leading to acquired resistance are observed in approximately 50% of 
GIST patients. The remaining cases with acquired resistance display alternative resistance 
mechanisms that are much less defined and include KIT and PDFRA amplification [11,13] and 
receptor tyrosine kinase switches from KIT to activation of FAK, FYN, or AXL [15–17]. 
 
A better understanding of the causes yielding imatinib resistance is necessary to improve 
treatment and outcomes. Here we performed a molecular comparison between a unique set of 
imatinib-naïve (IM-n) GIST samples (n = 33) and imatinib-resistant (IM-r) GIST samples (n 






Differentially Expressed microRNAs between 
Imatinib-Naïve and Imatinib-Resistant GIST 
Samples 
  
To investigate the molecular events underlying the acquisition of imatinib resistance in GIST 
we first determined the miRNA expression profiles in fresh frozen IM-n (n = 33) and IM-r (n 
= 20) GIST samples (Table 1). All imatinib resistant GIST patients displayed resistance after 
more than 6 months of imatinib treatment implicating acquired resistance mechanisms. Thirty-
five significantly (p < 0.01 and False Discovery Rate (FDR) < 20%) differentially expressed 
miRNAs were detected between the two groups (Figure 1, Table S1). Figure 1 depicts the heat 
map from a supervised hierarchical clustering. Two main clusters were discerned, one cluster 
contained 82% of the IM-n samples and the other cluster included 85% of all IM-r samples. A 
number of samples of both IM-r and IM-n GISTs were found to miscluster, a fact that could 
not readily be explained by differences in malignancy risk or tumor location. 
 
Secondary mutations in KIT are a frequent cause of imatinib-resistance in GIST. In the 20 IM-
r samples that we analyzed, nine displayed secondary mutations in KIT exon 13 (n = 3) and 
KIT exon 17 (n = 6), whereas in the remainder (n = 11) no secondary mutations were observed 
(Table 1). When we compared the miRNA expression profiles of IM-r samples with and 
without secondary mutations, we identified 22 miRNAs that were significantly (p < 0.01) 
differentially expressed and almost completely separated the two groups (Figure 2, Table S2). 





Table 1. Patient and tumor characteristics. 
Gastrointestinal Stromal Tumors Imatinib-Naïve (IM-n) 
Male  n = 23     
Female  n = 10     
Median age 
(range) 
65 (41–85)     
Sample 
code 


















X8KIT11 p.L576_R588dup/KIT11 Stomach intermediate   
X9.2.KIT11 p.W557_V559delinsF/KIT11 Stomach high    
X10KIT11 p.W557R/KIT11 Stomach intermediate    
X12KIT11 p.K550_V555del/KIT11 Stomach high    
X14KIT11 p.581_590insKWEFPRNRLS/KIT11 Stomach intermediate   
X23KIT11 p.W557_K558del/KIT11 Stomach intermediate    
X24KIT11 p.V554D/KIT11 Stomach intermediate   
X25KIT11 
p.W557_G592dup  
(c.1669_1774 + 2dup)/KIT11 




Mediastinum high    
X34KIT11 p.W557_V560delinsF/KIT11 Stomach high   




X39KIT11 p.L576P/KIT11 Duodenum intermediate   
X40KIT9 p.A502_Y503dup/KIT9 Colon 
overtly 
malignant 







X47KIT11 p.V559A/KIT11 Stomach low    










X55KIT11 p.W557_K558del/KIT11 Stomach intermediate    










X82KIT11 p.W557_P573delinsFQ/KIT11 Stomach 
overtly 
malignant 





















   
X101KIT11 p.E554_K558del/KIT11 Stomach low    












   
X119KIT11 p.Q556_I563del/KIT11 Stomach low   
 
Table 1. Cont. Patient and tumor characteristics. 
Gastrointestinal stromal tumors Imatinib-Resistant (IM-r) *** 
Male  n = 14      




49.5 (22–67)      
Sample 
code 
























p.L576P; c.1727  









































































































































































































p.V559D; c.1676  











* Tumor risk assessment was performed using AFiP criteria (Miettinen M. & Lasota, J. Semin. Diagn. 
Pathol. 2006, 23,70–83); ** Recurrent or metastatic disease during clinical follow-up; *** Patients were 





Figure 1. MicroRNA expression distinguishes imatinib-naïve (IM-n) from imatinib-resistant (IM-r) 
gastrointestinal stromal tumors (GIST). Fresh frozen tumor samples of IM-n and IM-r GIST patients were 
subjected to miRNA expression profiling. Depicted is the heat map of a supervised hierarchical clustering 
based on the 35 most significant (p < 0.01 and False Discovery Rate (FDR) < 20%) differentially expressed 
miRNAs. In the heat map red indicates relative high expression and green indicates relative low 
expression. The colored squares beneath the graph designate IM-n and IM-r samples, the malignancy risk 








mRNA Expression Profiling and Ingenuity Pathway 
Analyses Reveal Differentially Expressed Genes and 
Pathways in Imatinib-Naïve and Imatinib-Resistant 
GIST Samples 
 
In order to better understand the genes and molecular pathways involved in imatinib resistance 
in GIST we performed mRNA expression analyses on a subset (IM-r, n = 15 vs IM-n, n = 14) 
of our GIST samples. At least 352 genes were identified to be significantly differentially 
expressed (p < 0.008, FDR < 10%) between the two groups (Figure S1; Table S3). Figure 3 
shows the cluster tree of a supervised cluster analysis based on the expression of the 352 
differentially expressed genes represented by 475 different Affymetrix probe sets (Figure S1). 
All IM-r samples cluster together as do all IM-n samples except one. A molecular pathway 
analysis, focusing on canonical pathways and using the Ingenuity platform, was performed 
with the 352 differentially expressed genes as input. Among these genes, regulators of 
estrogen-mediated S-phase entry (p = 8.29 x 10-8 ), cyclins and cell cycle regulators (p = 3.09 
x 10-6), as well as checkpoint regulators of G2/M DNA damage (p = 8.64 x 10-6) were 
overrepresented (Figure S2). Of note, the cyclins A2, B1, B2, D2, and E2, as well as CDK1 
and the E2F transcription factors E2F7 and E2F8 were among the most differentially expressed 
genes found in two or more deregulated pathways (Table S4). Except for CCND2 (5.4 fold 
lower in IM-r), all the other seven genes displayed increased expression in IM-r with the fold 
changes of 2.6 for CCNA2, 2.9 for CCNE2, 2.3 for CCNB1, 2.1 for CCNB2, 3.0 for CDK1, 2.1 






Figure 2. MicroRNAs differentially expressed between imatinib-resistant gastrointestinal stromal tumor 
(GIST) samples with and without secondary mutations in KIT. Depicted is a heat map of a supervised 
hierarchical clustering based on the 22 most significant (p < 0.01) differentially expressed miRNAs in 
fresh frozen GIST samples with (green squares) and without (orange squares) secondary imatinib 
resistance causing mutations in KIT. In the heat map red indicates relative high expression and green 







Figure 3. Supervised hierarchical clustering based on differential gene expression discriminates imatinib-
naïve (IM-n) and imatinib-resistant (IM-r) gastrointestinal stromal tumor (GIST) samples. Transcript 
expression profiles were determined using the Affymetrix platform (U133 plus 2) of 29 fresh frozen 
samples derived of IM-n(n = 14) and IM-r(n = 15) GISTs. Depicted is the cluster tree of a supervised 
hierarchical clustering based on 352 significant (p < 0.008, False Discovery Rate (FDR) < 10%), 
differentially expressed transcripts. Note that 100% of the IM-r samples are clustered together with a single 
IM-n GIST sample. The colored squares beneath the graph designate imatinib-naïve and imatinib-resistant 
samples, the malignancy risk and location of the tumors (see Figure 1). Note that the sample codes below 
also indicate which KIT exon is mutated. 
 
An ingenuity pathway analysis (IPA) was also conducted to examine interactions within the 
352 most differentially expressed genes between IM-r and IM-n GIST samples. Figures 4A 
and 4B depict two of the largest and most significant interaction networks revealed by IPA 
(see for a symbol legend Table S5). Figure 4A displays associations between genes involved 
in cell cycle regulation and consequently cell proliferation. Cyclin A and cyclin E appear as 
central hubs in the gene network. The interaction network shown in Figure 4B also supports 
cell cycling and cell proliferation judged by the overexpressed central genes cyclin dependent 
kinase 1 (CDK1), aurora kinase B (AURKB), and forkhead box protein M1 (FOXM1). CDK1 
plays a key role in cell cycle regulation, AURKB regulates the segregation of chromosomes 
and the spindle checkpoint in mitosis and FOXM1 is a transcription factor essential for cell 










Integration of Differentially Expressed microRNAs 
and mRNAs into Networks 
 
Using IPA, we investigated whether interaction networks between mRNAs and miRNAs could 
be defined to identify and better understand the possible regulatory role of miRNAs-mRNAs 
interactions in imatinib resistance. To be able to directly compare mRNA with miRNA 
expression in the same GIST samples, we considered only the differentially expressed 
miRNAs in the subset of GIST samples that were analyzed by mRNA expression profiling. 
We identified 88 differentially expressed miRNAs (p < 0.03, FDR < 30%) (Table S6). Note 
that almost 70% of the differentially miRNAs reported in Figure 1 and Table S1 were present 





















Figure 4. Ingenuity Pathway Analysis indicates the relation between genes differentially expressed 
between imatinib-naïve (IM-n) and imatinib-resistant (IM-r) gastrointestinal stromal tumor (GIST) 
samples. The 352 significant differentially expressed genes between IM-r and IM-n GIST samples were 
used as input for an Ingenuity Pathway Analysis (IPA). The depicted IPA networks illustrate and visualize 
associations between the genes. (A) IPA network highlighting cell cycle related, differentially expressed 
genes. (B) IPA network highlighting CDK1, AURKB, and FOXM1 interactions. Green and red shading 





The gene-miRNA network presented in Figure 5 included most regulatory gene-miRNA 
interactions and related to cell cycle regulation. The network highlights regulation by miR-
92a-3p, miR-99a-5p, and miR-101-3p. The differential expression of selected miRNAs and 
mRNAs, which were indicated in the text and IPA analyses, were verified by RT-PCR, thereby 




Figure 5. Ingenuity Pathway Analysis integrating differentially expressed genes and microRNAs between 
imatinib-naïve (IM-n) and imatinib-resistant (IM-r) gastrointestinal stromal tumor (GIST) samples. As 
input for an Ingenuity Pathway Analysis (IPA) the significantly differentially expressed transcripts (352 
genes, p < 0.008, False Discovery Rate (FDR) < 10%) and miRNAs (88 miRNAs, p < 0.03, FDR < 30%) 
from the same set of IM-r (n = 15) and IM-n (n = 14) GIST samples were used. The depicted network 
indicates miRNA–gene interactions relevant in context of the cell cycle. Green and red shading indicates 





To better understand the mechanisms that account for imatinib resistance, here we molecularly 
characterized at an mRNA and miRNA level a unique set of IM-n and IM-r GIST samples. 
Bioinformatic approaches were used to identify signaling pathways and gene networks 
modulated in imatinib-resistant GISTs. The reason to look for differentially expressed 
miRNAs between IM-n and IM-r samples is based on the observations that miRNAs are 
intimately involved in GIST pathobiology [18,19] and well-known actors in drug resistance 
mechanisms occurring in cancer types other than GIST [20]. Indeed, we identified miRNAs 
that distinguished IM-r from IM-n GIST samples. Although the fold changes observed were 
relatively small, they can still have a significant impact on protein levels because the regulation 
of multiple targets within the same pathway can amplify their biological effect [21] and 
different miRNAs may cooperate and have synergistic effects [22]. Previously few other 
groups studied miRNA expression in relation to imatinib-resistance in GIST as well [23,24]. 
Akaçakaya et al. compared miRNA expression profiles of 17 GISTs of which 10 responded to 
imatinib (imatinib-sensitive) and seven progressed on imatinib (imatinib-resistant) [23]. They 
identified ten differentially expressed miRNAs a.o. miR-125a-5p that were found to be 
overexpressed in IM-r GIST and of which the expression was inversely correlated to levels of 
protein tyrosine phosphatase, non-receptor Type18 (PTPN18) [23]. The lowered PTPN18 
levels conferred imatinib resistance in GIST822 cells. In a recent follow-up paper evidence 
was provided that the miR-125a-5p and PTPN18 effects on imatinib resistance were mediated 
through phosphorylated FAK levels [25]. Shi et al., reported downregulation of miR-518a-5p 
in IM-r that targets PIK3C2A [24]. Unfortunately, PIK3C2A levels were not modulated to 
validate its levels affecting imatinib sensitivity in GIST cells. Similarly, no evidence for an 
inverse correlation between miR-518a-5p and PIK3C2A expression in clinical samples was 
presented. The overlap in miRNAs detected between these studies and ours is limited, most 
likely due to different experimental set-ups, including the exact nature and number of GIST 
samples analyzed and the use of different miRNA detection platforms. In chronic myeloid 
leukemia (CML), another malignancy that is treated with imatinib, miRNAs have also been 
linked to imatinib resistance [26–28]. A number of miRNAs, e.g., miR-99a, miR-30c, and 
miR-101, which were all found downregulated in the IM-r samples (Table S6), have been 
previously associated with imatinib resistance in GIST or chronic myeloid leukemia [26,27]. 
The observed downregulation of miR-30c and miR-181a in our IM-r samples corresponded to 
findings in CML in which lowered expression of these miRNAs was also found in imatinib 
resistant cells [27,28]. In most cases dysregulated miRNAs in the IM-r setting were not further 
functionally characterized to substantiate their roles and involvement in imatinib resistance.  
 
Interestingly, the miRNA expression profiles were able to distinguish IM-r GIST samples with 
and without secondary KIT mutations. This observation may reflect a different biology 
underlying the resistance phenotype in the two groups. However, the accompanying fold 
differences in miRNA expression are small. To verify our findings larger sample cohorts should 




Pathway and network analyses using differentially expressed transcripts and mRNAs as input 
indicated the upregulation of multiple cell-cycle related genes in the IM-r GIST samples. The 
cyclins A and E are well-known regulators of G1/S, S, and G2/M transition phases. Their 
increased expression levels, as well as those of most other genes in the network, most likely 
facilitates cell cycling and consequently cell proliferation. In this context the reduced 
expression of cyclin dependent kinase inhibitor 1 C (CDKN1C), a negative regulator of cell 
proliferation, also makes sense. However, the reduced expression of cyclin D2 (CCND2) does 
not seem to fit as its expression was found downregulated in the IM-r samples. It is unclear to 
what extent these findings are merely a reflection of the progressive nature of the IM-r GISTs. 
Aberrant expression of the majority of these genes is known to be involved in drug-resistance 
in various cancer types [29–31]. Of interest is the increased expression of the atypical E2F 
transcription factor family members E2F7 and E2F8. The precise function of these E2F family 
members in GIST and other cancers is still ill-defined. E2F7 overexpression has been linked 
to tamoxifen and anthracycline resistance in breast cancer and head and neck squamous cell 
carcinoma, respectively [32,33]. E2F8 promotes cell proliferation and tumorigenicity in breast 
cancer [34] and cisplatin resistance to estrogen receptor positive breast cancer cells [35]. The 
increased cell cycle activity may render IM-r GIST sensitive to cell cycle inhibitors. 
 
The other highlighted gene interaction network is also conducive of cell cycle progression. 
This network points to central roles for AURKB and FOXM1 of which the expression was 
increased in IM-r GISTs. AURKB, together with AURKA, which is also upregulated in IM-r 
samples (Table S3), are serine/threonine kinases that regulate mitosis. These genes are found 
upregulated in many cancers and targeted inhibitors have been developed [36]. In GIST 
AURKA expression has been identified as a negative prognostic factor [37,38] and has 
recently been implicated as a therapeutic target [39]. The significance of FOXM1 in GIST was 
recently emphasized by reporting its role in GIST progression [40]. Furthermore the FOXO3a–
FOXM1 axis has been implicated in cancer related processes like proliferation, survival, drug 
resistance, angiogenesis, migration, and DNA repair in other cancers [41]. Perhaps FOXM1 
overexpression can be therapeutically exploited, e.g., by using thiazole antibiotics. 
 
The integrative network analyses implicated some of the differentially expressed miRNAs as 
regulators of cell cycle related genes. Of special interest is miR-92a-3p, which is predicted to 
target CDKN1C through a highly conserved binding site in its 3’UTR, as predicted by 
TargetScan v7.2 (http://www.targetscan.org).The downregulation of miR-99a-5p affects 
mTOR levels [42,43]. The upregulation of mTOR stimulates cell cycle progression through its 
cell growth effectors S6K1 and eIF4E [44]. Finally, miR-101-3p has been implicated in 
imatinib sensitivity in CML with high levels sensitizing to imatinib through the 
downregulation of JAK2 and inhibition of NF-κB target genes [26]. So conversely miR-101-
3p downregulation might cause imatinib resistance. Furthermore miR-101-3p regulates the 
PI3K/AKT/mTOR pathway [45,46] mediating AKT activation, which may reduce CDKN1C 
levels [47].  
 
Our findings demonstrated that IM-r GIST samples can be distinguished from IM-n GIST 
samples based on their miRNA and mRNA expression profiles. In addition, we identified 
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several miRNAs that discriminated between IM-r GIST samples with or without secondary 
KIT mutations. Pathway and network analyses highlighted cell cycle related genes/gene 
networks in IM-r GISTs and identified overexpressed proteins that may be pharmacologically 
targeted using small molecule inhibitors. Further, our data implicated at least three miRNAs, 
miR-92a-3p, miR-99a-5p, and miR-101-3p, as potential effectors of imatinib resistance. Future 




Materials and Methods  
 
Patient Samples  
 
Fresh frozen GIST samples (n = 53) were obtained from the tissue bank of the Department of 
Pathology of the University Hospitals Leuven, Belgium and the Department of Soft 
Tissue/Bone Sarcoma and Melanoma, Marie Skłodowska-Curie Institute, Oncology Center, 
Warsaw, Poland. The initial GIST diagnosis was based on histological features as assessed by 
an expert pathologist, immunostaining for CD117/KIT and anoctamin (ANO1 or DOG1), and 
the presence of KIT mutations. All tumor samples that were analyzed contained >80% tumor 
cells, contained KIT activating mutations, and were derived from both IM-n (n = 33) and IM-
r (n = 20) GISTs. The pathological and initial diagnostic molecular evaluation were all 
performed in a single institution (KU Leuven). Clinicopathological characteristics concerning 
patients and tumors are listed in Table 1. The majority of the patients from whom the GIST 
samples were derived were diagnosed and treated from 2000 to 2011 according to the applicable 
guidelines in that time-period. All patients consented to use their tissues for research purposes 
and approval was obtained from the Ethics Committee of the University Hospitals Leuven 
(ML7481) and the Oncology Center, Warsaw, Poland. The study was carried out in the context 
of a research protocol “Translational research in soft tissue sarcomas”, which was reviewed 
and approved by the Medical Ethical Review board of the Erasmus Medical Center (MEC-




RNA Isolation and microRNA Profiling 
 
Total RNA was isolated from fresh frozen tumor samples using RNAbee (Tel Test Inc., 
Friendswood, TX, USA) following the standard extraction protocol recommended by the 
manufacturer. RNA concentration and quality were examined using a Nanodrop-1000 
(Nanodrop Technologies, Wilmington, DE, USA). MiRNA expression profiles were 
determined using miRNA microarrays, essentially as described before by Pothof et al. [48]. In 
brief, using the Kreatech ULSTM aRNA labeling Kit (Kreatech Diagnostics/Leica Biosystems, 
Amsterdam, the Netherlands), 1 μg total RNA was labeled with Cy3. The Cy3-tagged RNA 
was hybridized overnight to LNA™ modified oligonucleotide capture probes (Exiqon, 
Vedbaek, Denmark) spotted in duplicate on Nexterion E slides. Of the 1344 capture probes on 
the slides, 725 were specifically designed to detect human miRNAs. After hybridization, slides 
were scanned, and median spot intensity was determined using ImaGene software 
(BioDiscovery Inc., El Segundo, CA, USA). After background subtraction, expression values 
were Quantile normalized using R-software, bad spots were deleted, and duplicate spots 
averaged. The normalized miRNA expression data were log 2 transformed and median 
centered to acquire the relative expression values that were used for hierarchical clustering 
analysis using the open source software Cluster 3.0 [49] and Java Tree View [50]. A two-
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sample t-test was used to determine statistical significance (p < 0.05) between imatinib-naïve 
and imatinib-resistant samples and the Benjamini–Hochberg false discovery rate (FDR) was 
used to control for multiple testing. The miRNA expression datasets generated and analyzed 
during the current study are presented in Table S7. 
 
 
mRNA Expression Analysis 
Gene expression analysis using the Affymetrix HG-U133_Plus_2 platform (Affymetrix, Santa 
Clara, CA, USA) was carried out according to standard operating procedures by the VIB 
MicroArray Facility of the KU Leuven. Raw. cel files were processed using fRMA parameters 
(median polish) after which batch effects were corrected using ComBat. [51,52]. BRB-Array 
tools (Biometric Research Branch Array Tools (http://brb.nci.nih.gov/BRB-ArrayTools/) was 
used for analyzing the transcript expression data and a two-sample t-test was used for statistical 
testing. The mRNA expression datasets generated and analyzed during the current study have 






The differential expression of selected miRNAs in IM-n (n = 33) and IM-r (n = 20) GIST 
samples, as detected by the LNA™ modified oligonucleotide platform, was validated by RT-
PCR using the TaqMan® MiRNA Assays Technology (Applied Biosystems/ThermoFisher 
Scientific, Bleiswijk, the Netherlands). In brief, total RNA (50 ng) was reverse transcribed in 
a multiplex reaction using specific miRNA primers from the TaqMan® MiRNA Assays and 
reagents from the TaqMan® MiRNA Reverse Transcription Kit (Applied 
Biosystems/ThermoFisher Scientific) according to the manufacturer’s protocol. The resulting 
cDNA was used as input in a quantitative real-time PCR (qPCR) using a miRNA specific 
primer/probe mix together with the TaqMan® Universal PCR Master Mix No AmpErase® 
UNG (Applied Biosystems/ThermoFisher Scientific) using the 7500 Fast Real-Time PCR 
systems (Applied Biosystems). The qPCR data were analyzed using SDS software (version 
2.4, Applied Biosystems/ThermoFisher Scientific). A standard dilution series of a cDNA 
sample-pool was included on every plate allowing for the absolute quantification of the 
miRNA expression.  
 
The differential expression of selected mRNAs in IM-n (n = 33) and IM-r (n = 20) GIST 
samples, as detected by the Affymetrix platform, was validated by RT-PCR using the 
TaqMan® Technology (Applied Biosystems/ThermoFisher Scientific). In brief, total RNA (1 
µg) was used as input for a reverse transcription reaction using a high capacity cDNA reverse 
transcription kit (Applied Biosystems/ThermoFisher Scientific) according to procedures by the 
manufacturer. The cDNA was used in a PCR reaction using primer/probe combinations from 
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the following Taqman® gene expression assays (AURKA, assay ID: Hs01582072_m1; 
AURKB, assay ID: Hs00945858_g1; CCND2, assay ID:Hs00153380_m1; CCNE2, assay ID: 
Hs00180319_m1; CDK1, assay ID: Hs00938777_m1; CDKN1C, assay ID: Hs00175938_m1; 
E2F7, assay ID: Hs00987777_m1; FOXM1, assay ID: Hs01073586_m1) and Taqman® 
Universal PCR master mix using the 7500 Fast Real-Time PCR system (all obtained from 
Applied Biosystems/ThermoFisher Scientific) according to the manufacturer’s 
recommendations. Three housekeepers (GAPDH, HPRT, and PPIA) were used for 
normalization purposes using the comparative CT-method. The qPCR data were analyzed using 





For pathway analyses, a commercial software application, Ingenuity® Pathway Analysis 
(IPA®) (Qiagen, Hilden, Germany), was used. IPA calculates and visualizes the known 
pathway associations and interactions between sets of transcripts. mRNAs and/or miRNAs that 
were significantly differentially expressed between IM-n and IM-r samples were selected and 
accompanying identifiers and fold changes were uploaded into the IPA. The mRNA data were 
used to identify canonical signaling and metabolic pathways that were predicted to be activated 
or inhibited (canonical pathway analysis). The miRNA and mRNA data together were used to 
construct interaction networks, networks based on molecular relationships between 
differentially expressed mRNAs and/or miRNAs. These networks were matched to and 
derived from a ‘’global molecular network’’ developed from the available online information 
in the IPA. The pathway and network analyses were performed using filtering of ‘’Human’’ 
and ‘’uncategorized’’ for species as well as ‘’direct and indirect relationships’’ for general 
settings. The presented networks were representations of molecular relationships between 





The following are available online at www.mdpi.com/xxx/s1: Table S1, Differentially 
expressed microRNAs between imatinib-naïve and imatinib-resistant gastrointestinal stromal 
tumors; Table S2, Differentially expressed microRNAs between imatinib-resistant 
gastrointestinal stromal tumors with and without secondary KIT mutations; Table S3, List of 
352 differentially expressed genes between imatinib-resistant and imatinib-naïve GIST 
samples; Table S4, Differentially expressed genes associated with the top deregulated 
canonical pathways; Table S5, Ingenuity Pathway Analysis Symbols; Table S6, Differentially 
expressed microRNAs between imatinib-naïve and imatinib-resistant gastrointestinal stromal 
tumors in the samples that were used for mRNA profiling; Table S7, Overview of the 
microRNA expression levels measured in the imatinib-naïve and imatinib-resistant 
gastrointestinal stromal tumor samples; Figure S1, Differentially expressed mRNAs between 
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imatinib-naïve and imatinib-resistant GIST samples; Figure S2, Top deregulated canonical 
pathways between imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors; 
Figure S3, Quantitative RT-PCR validation of differentially expressed microRNAs and 
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Cancer is globally one of the leading causes of death ranking second after cardiovascular 
disorders. As cancer is often diagnosed at a late stage, scientists and clinicians aim to define 
prevention and early detection methodologies. At the same time ways to reliable stratify 
patients and novel treatments strategies are being developed. These ongoing efforts will 
ultimately improve patient care. Soft tissue sarcomas (STS) comprise approximately 1% of all 
adult tumors and 10% of all pediatric cancers. STS are a group of rare and heterogeneous 
tumors, mainly of mesenchymal origin that currently include more than 50 different 
histological subtypes [1]. Roughly this group can be divided into three main categories; small 
blue round cell tumors (SBRCTs), gastrointestinal stromal tumors (GIST) and (adult) STS. 
Different STS have a different etiology, diverse genomic aberrations and different 
morphologies and clinical features. This and their rarity, makes STS a challenging group of 
tumors to study in the laboratory and treat in the clinic. 
 
In particular for patients with advanced-non-GIST-STS where cure by surgery or radiotherapy 
is not possible, the prognosis is dismal. Chemotherapy is the only remaining treatment option 
for these patients. Despite the advent of several new treatment strategies such as the second-
line treatment options, trabectedin for leiomyosarcomas and liposarcomas, pazopanib for non-
adipocytic STS, and eribulin for liposarcomas [2], the survival of advanced non-GIST STS 
patients is often less than one year. Therefore, there is a pressing medical need to further 






In order to meet the challenges outlined above, a better and more thorough understanding of 
STS tumor biology is indispensable. Modern molecular technologies have greatly advanced 
our knowledge of cancer with the identification of genes, including non-protein coding genes, 
and signaling pathways involved in carcinogenesis [3]. However, due to their rarity and 
heterogeneity, insight into the biology of STS is somewhat lagging behind. 
  
MicroRNA (miRNA) expression profiling is one of the approaches that can be used to 
molecularly characterize tumors. MiRNAs are small (18-25 nucleotides in length) non-protein 
coding RNA molecules, which exert regulatory roles on the expression of various genes. 
Binding of miRNAs, facilitated by the RNA induced silencing complex, to the untranslated 
regions (3’ or 5’ UTR) or the open reading frame (ORF) of target mRNAs leads to mRNA 
degradation and/or translation inhibition [4-6]. Numerous studies have already reported the 
involvement of the de-regulated miRNAs in tumorigenesis and tumor progression in multiple 
cancer types. These miRNA molecules can act as tumor suppressors or oncogenes [7, 8]. The 
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molecular reasons why miRNAs are aberrantly expressed, how they interfere with biological 
processes and contribute to tumor biology are topics actively being studied in many cancer 
types. Currently miRNAs are used, or being used, as biomarkers for diagnostic, prognostic and 
predictive purposes. Another intriguing exploitation of miRNAs in the context of cancer is 
their use as therapeutic agents that is currently being investigated [9]. Using antisense 
oligonucleotides (anti-miRNAs) or miRNA mimics dysregulated miRNA expression levels 
can be normalized for therapeutic purposes. 
 
In view of the importance of miRNAs in tumor biology, their involvement in sarcomagenesis, 
use as diagnostic and prognostic biomarker and their therapeutic potential, miRNAs are 
increasingly being studied in various STS entities [10].  
 
 
(I) Malignant peripheral nerve sheath tumors  
 
One of the STS entities in which molecular characterization, including unraveling the role of 
miRNAs, hopefully will lead to better outcomes is the group of malignant peripheral nerve 
sheath tumors (MPNSTs). MPNSTs are aggressive and chemo-resistant STS with a propensity 
to metastasize. About half of these tumors arise from a benign counterpart named plexiform 
neurofibromas in neurofibromatosis type 1 (NF1) patients while the rest develops sporadically. 
Available treatment options for patients with unresectable and advanced disease include 
doxorubicin-based chemotherapy in the first line setting and pazopanib in the second-line [11, 
12].  An overall poor response to chemotherapeutic regimens and the aggressive nature of these 
tumors, make their treatment challenging. This translates into poor prognosis and high 
mortality rates for MPNST patients. A better understanding is required of the biology of these 
rare tumors to more clearly define the molecular mechanisms driving tumorigenesis, which 
will subsequently aid in the development of novel and more effective therapies. 
 
Topoisomerase 2-α (TOP2A) is a direct molecular target of doxorubicin. This drug forms the 
basis of the current first-line treatment for advanced MPNST patients. It is known that TOP2A 
is more abundantly expressed in MPNST than in the benign counterpart i.e. plexiform 
neurofibromas [13, 14]. Despite the high level of TOP2A, advanced MPNST patients do not 
respond well to doxorubicin and face a dismal prognosis with a 2 year overall survival of 20%. 
To improve the efficacy of doxorubicin one could adjust the doxorubicin dose relative to the 
expression level of TOP2A in a patient-specific manner. We therefore investigated the relation 
between TOP2A level and sensitivity for doxorubicin in a panel of MPNST cell lines [14]. To 
overcome the drug resistance displayed by MPNST we need to understand which resistance 
mechanisms underlie the observed drug insensitivity. In general this is not an easy task as drug 
resistance in cancer appears to be a multifactorial phenomenon with multiple resistance 
mechanisms operating at the same time. The involvement of several factors such as 
epigenetics, drug efflux, drug target alterations, cell death inhibition, cancer cell heterogeneity, 
etc. has made the understanding of the underlying resistance mechanisms and ways to 




We also investigated the expression of other potential targetable molecules in MPNST. A 
bromodomain family member (BRD4) [17] and a PRC2 core element (EZH2) [18, 19] were 
both reported to be up-regulated and the therapeutic use of inhibitors specific for BRD4 and 
EZH2 was suggested. In fact, specific small molecules targeting these proteins are being 
assessed in clinical trials for several cancer types [20-22], making BRD4 and EZH2 indeed 
potential drug targets in MPNST treatment.  However, we could not confirm the upregulation 
of BRD4 in human MPNST samples nor could we demonstrate that inhibition of the of BRD4 
or EZH2 interfered with cellular proliferation in our MPNST cell line panel. On the basis of 
our findings, we concluded that the clinical benefits of using inhibitors against BRD4 and 
EZH2 individually for MPNST treatment, is limited. 
  
The apparent discrepancy between our findings and former investigations [17-19] could be 
due to the utilized laboratory models (i.e. cell lines and more advanced genetically engineered 
mouse models), which may not be appropriate representatives of the tumors encountered in 
the patient. In a subsequent study to identify driver miRNAs in MPNST we have attempted to 
address this issue by examining paired human samples comparing plexiform neurofibromas 
and MPNST that arose in the same patient over time. Using paired samples may remove some 
of the interpatient heterogeneity encountered when comparing non-paired tumor samples. Our 
study revealed miRNAs that were differentially expressed between plexiform neurofibroma 
and MPNST samples. When we functionally characterized selected miRNAs using an MPNST 
cell line panel we noted that not all cell lines responded equally to miRNA modulation. After 
ruling out technical explanations we concluded that these observations may be due to tumor 
heterogeneity that affects the way and intensity with which  MPNST cells respond to miRNAs 
(Chapter 3). 
 
Due to the rarity of MPNST its genomic landscape is incompletely known [3]. Of note, in 
about 60% of NF1-associated MPNST mutations and deletions are observed in SUZ12 or EED 
[23-25]. These proteins are core components of the PRC2 complex, which is an epigenetic 
regulator. The genomic aberrations in MPNST cause inactivation of the PRC2 complex 
thereby affecting the gene expression profile. 
  
The observations made in our two studies regarding MPNST [14]( Chapter 3) highlight the 
importance of incorporating relevant laboratory models for both exploratory and confirmatory 
aspects of the pre-clinical studies. In addition, sample sizes must be able to capture inter- and 
intratumoral heterogeneity present and appropriate controls must be included in the study. This 
is not always evident when working with rare and relatively ill-defined tumors such as 
MPNST. Limitations in the available pre-clinical tools are considered a challenge in obtaining 
reproducible and reliable research findings in oncology, which is a major concern and has been 
addressed repeatedly [26, 27]. As patients are ultimately the main focus of all efforts within 
cancer research, investigators must consider and include robust and representative pre-clinical 
tools in order to make reproducible discoveries. This will improve the translation of laboratory 




(II) Gastrointestinal stromal tumors   
 
Gastrointestinal stromal tumors (GIST) are rare tumors of the gastrointestinal tract 
predominantly associated with the stomach (~60%) or small intestine (~30%) [28]. Activating 
mutations in KIT are recognized as one of the most common and crucial events in GIST 
pathogenesis [29]. On the clinical level, imatinib mesylate (a drug targeting KIT) has 
dramatically improved the outcome of advanced patients from a median overall survival (OS) 
of 9 months before the drug treatment to 5 years [30] and a progression-free survival (PFS) of 
about 2 years with a response rate of approximately 50% [31]. The GIST patient’s response to 
imatinib treatment is known to be correlated with the mutational status of the KIT gene. For 
instance those patients harboring a KIT exon 9 mutant are more likely to show progression 
within 6 months of the initial imatinib treatment than patients with other mutations. [32, 33]. 
Although, most patients respond favorable to imatinib, the vast majority of patients eventually 
develop resistance leading to tumor progression. Despite second and third line options such as 
sunitinib and regorafenib, the prognosis for advanced GIST patients who failed to imatinib 
remains poor. Therefore, to overcome drug resistance one needs to decipher and understand 
the underlying resistance mechanisms.  
 
In GIST – similar to the situation encountered in many other cancers – miRNAs are intricately 
involved in the process of tumorigenesis. Furthermore miRNAs expression profiles can be 
used to classify stage of the tumors, to identify tumor location, and indicate GIST mutational 
status (Chapter 5). Also miRNAs have been implicated as therapeutic agents as their 
modulation interfered with GIST cell line proliferation and induced apoptosis or re-sensitized 
imatinib resistant (IM-r) tumors. For instance, in vitro inhibition of the expression level of 
miR-125-5p increased the sensitivity of GIST882R (IM-r) cells for imatinib [34]. In this 
context, in 2013, our group examined the therapeutic potential of restoring the expression of 
the dysregulated miR-221/222 and miR-17-92 clusters. The re-expression of downregulated 
miR-17, mir-20a and miR-222 in GIST cells affected cellular proliferation, induced apoptosis 
through targeting c-KIT and ETV1 [35]. 
  
In the context of imatinib-resistance in GIST we molecularly analyzed 53 fresh frozen GIST 
samples derived from imatinib-naïve (n=33) and imatinib-resistant (n=20) GISTs. We 
identified differentially expressed genes and miRNAs and performed an Ingenuity Pathway 
(IP) Analysis to reveal gene-miRNA interaction networks associated with acquired imatinib-
resistance. At least three miRNAs (miR-92a-3p; miR-99a; miR-101-3p) were highlighted that 
directly or indirectly affect the expression of cell cycle regulators. In addition a number of 
genes were revealed, some of which targetable by small molecules, that appeared to fulfil hub-
like function within the gene-gene and gene-miRNA interaction networks. In follow-up 
experiments using imatinib-sensitive and imatinib-resistant cell line and PDX models, it 






Challenges in soft tissue sarcoma pre-clinical studies 
  
Many pre-clinical studies have focused on the elucidation of biological processes that drive 
STS tumorigenesis. However, potential effective treatment strategies coming forth from these 
pre-clinical studies could not be easily translated to the clinic and/or have not yet reached 
clinical routine. Many different factors contribute to this unwanted gap between laboratory and 
clinic. 
 
Tumor heterogeneity  
 
One of the hallmarks of cancer is genomic instability [36] which leads to intra- and 
intertumoral diversity within and between individuals. Therefore, a single biopsy of a lesion 
does probably not fully capture the heterogeneity present in a patient’s cancer. To overcome 
this hurdle, biopsies should be taken from multiple lesions in a patient and each lesion should 
be biopsied more than once. Ideally, but this may be difficult to implement in the clinical 
setting, biopsies should be taken at multiple time-points during the disease. This will enhance 
the precision and provide a better reflection of the heterogeneity within a single lesion and 
between lesions in the same patient. This holds true for GIST patients as often the complex 
nature of this tumor is not adequately reflected in the currently available pre-clinical studies 
due to the use of a single biopsy of one lesion. Despite the rarity, multiple primary GIST 
(MPG) harboring different KIT/PDGFR mutations within one individual have been detected. 
These mutational diversities have substantial impact on defining suitable treatment profile for 
the patient [37].  
 
Moreover, variation across patients diagnosed with the same tumor type also makes 
investigations on tumor biology and the subsequent discovery of effective/novel therapeutic 
molecules challenging. Available animal models used for pre-clinical research are known to 
mainly carry a combination of limited genetic aberrations presented in a subset of tumors and 
may not represent the full genomic complexity present in tumors. To elaborate further on this 
statement, the available MPNST xenografts animal models most likely represent very late 
stages of MPNST only, whereas genetically engineers animal models for MPNST usually only 
reproduce part of the malignant transformation process as it occurs in patients [38]. In NF1 
patients MPNSTs arise from plexiform neurofibromas via a distinct intermediary form called 
atypical neurofibromas. To our knowledge no genetically engineered animal model faithfully 
reproduces this sequence of events. This could be due to the absence of crucial mutations in 
these models, necessary for tumorigenesis in humans. As an example, the loss of SUZ12 in a 
subset of MPNSTs [23], which influences the obtained outcome from (pre)clinical studies, is 
among the vital mutations being neglected. SUZ12 is an essential element of the polycomb 
repressive complex 2 (PRC2), which is a well-known complex involved in epigenetic 
modulation of gene expression [39]. Inactivation of PRC2 upon SUZ12 loss will result in 
aberrant genes expressions and ultimately diversities in the (pre)clinical outcomes. On the 
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basis of these findings, in our effort to functionally characterize the chosen differentially 
expressed miRNA candidates, we detected that distinct NF-associated MPNST cell lines 
respond with diverse intensities or in a different fashion to miRNAs modulations. It could be 
that the MPNST cells lines in our cell line panel differ at a molecular level, perhaps due to 
variable chromosomal copy number alterations as frequently observer in MPNST. Moreover, 
our inability to recapitulate outcomes obtained from prior studies could also be explained by 
the existence of this genetic diversity (Chapter 2). For example, the discrepancy in validating 
the outcome of the expression level of BRD4 and in vitro modulation of this potential drug-
target upon JQ1 induction were among the challenges we faced [14].  
 
In addition to the above-mentioned hurdles, the tumor micro-environment may also 
significantly contribute to heterogeneity and affect the response to clinical interventions. Of 
importance are also processes like hypoxia and inflammation that modulate the tumor micro-
environment. Therefore, to obtain translatable outcomes from pre-clinical oncogenomic 
studies, which result in significant patient benefit, the use of patient-specific (personalized) 
model in laboratories is needed. These models can enhance our knowledge on individual needs 




Despite the wide spectrum of studies being conducted on STS, these tumor types still remain 
a major challenge to medical oncologists and research scientists. The genomics of STS remain 
understudies therefore the development of STS, particularly the underlying genomic 
aberrations, are not thoroughly understood, which poses difficulties in obtaining successful 
treatment outcome. Thus, extra focus the mechanisms underlying disease onset and 
progression is necessary. To this end, utilizing reliable laboratory models for generating 
reproducible and translatable findings for the clinic is strongly warranted. However, as more 
has been learned from the use of the currently available models, the relevance and reliability 
of such models are extensively debated [26, 27].  
 
(I) Induced pluripotent stem cells   
 
Pro’s 
The recently developed induced pluripotent (iPS) technology can not only be utilized for 
disease modeling purposes [40-42] but is also as an attractive technique to create new pre-
clinical models for cancer [43, 44] (Fig.1). First, induced pluripotent stem cells (iPSCs) can be 
derived from normal cells or patients cells e.g. skin fibroblasts from NF1 patients. 
Subsequently cancer-specific genomic aberrations ca be introduced e.g. by CRIPS-CAS9 and 
their effects studied at a molecular level by differentiating the cells towards the cell type in 
which the cancer phenotype will be fully revealed. Alternatively, iPSCs can be generated from 
cancer cells. It is likely that tumorigenicity is lost upon reprogramming and will reappear at a 
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certain cell-stage during differentiation when the tissue-specific epigenetic pattern allows the 
already present cancerous mutations in oncogenes and/or tumor suppressors to exert their 
effect. This process gives insights into the complex genetic aberrations from the initial phases 
of disease onset to a full-blown cancer. It will not only facilitate understanding tumor biology 
but will help scientist and clinicians to find reliable treatment approached. Therefore, cancer-
derived iPSCs can be differentiated (in vitro & in vivo) towards the cell lineage the cancer 
originated from, enabling researches to probe the biology of tumor initiation, early progression 
and metastasis of human tumors. This approach can lead to the discovery of the molecular 
networks underlying tumor initiation and tumor progression, the detection of novel biomarkers 
indicating the early stages of cancer development and gives the possibility for high-throughput 
drug screens. As well, the recent advance in CRISPR-CAS9 genome editing technology adds 
another dimension to the use of iPSCs as treatment for human disease [45].  
 
Con’s 
Although, despite the great advances in the use of patient-derived iPSCs as cancer models, it 
is worth noting that also this technology is far from perfect due to genomic instabilities that 
are introduced during reprogramming, the heterogeneity in differentiation potency of iPSCs 
(transcriptional and epigenetic variabilities), challenging reprogramming and differentiation 
approaches for modeling cancer cells, and difficulties in monitoring tumorigenesis upon iPSC-
derived cancer cells re-differentiation (in vitro or in vivo). Moreover, these models do not fully 
represent the tumor microenvironment. Some might suggest the injection of patient-derived 
iPSCs in an animal model to compensate for the absence of tumor microenvironment in 2D 
culture; however, the cross-species and biological variabilities in the process of tumorigenesis 
between animals and human should not be overlooked [46, 47]. 
 
 
(II) Organoids & spheroids    
 
Pro’s 
To compensate for many of these deficiencies, other approaches such as tumor organoid and 
spheroid models are also among the new promising pre-clinical modeling systems [48]. For 
instance, one of the substantial advantages of using 3D culture systems over the traditional 2D 
monolayer cultures, is the feasibility of co-culturing/incubating patient-derived organoids with 
immune cell suspensions (ideally derived from the same patient) [49]. As inflammation is 
among the major causes of complex tumorigenesis, this approach will provide a more robust 
pre-clinical model for investigating inflammation-related carcinogenesis mechanisms as well 
will mimic patient-specific immune responses upon applying immunotherapeutic anti-cancer 
drugs. This model simulates the complex nature of cancer and its relation with the 
microenvironment. In addition, to having the capability to introduce components of the tumor 
microenvironment, the study of drug penetration and cell-cell interaction are also an asset of 





Similar to iPS technology, developing patient-specific organoid models also face challenges 
as for instance these models lack the ability to fully capture tumor microenvironment and its 
biological features. The interaction between the tumor cells and surrounding stromal cells, as 
well as cells from blood and lymphatic vessels are known to be crucial for immuno-therapy 
[50]. Therefore more effort in optimizing, improving and developing optimal growing 
conditions for these 3D models are expected in the future.      
 
 
(III) Tumor material    
 
Apart from the aforementioned difficulties within cancer research, in sarcoma studies 
acquiring enough materials for developing novel pre-clinical models requires a considerable 
amount of effort due to the rarity of these tumors. Often affected individuals are treated across 
various hospitals as a consequence of which there is limited accessibility to tumor materials 
for research purposes. Therefore, to collect sufficient high-quality materials, a closer 
cooperation between various (inter)national sarcoma centers of expertise as well as scientists 
and clinicians is strongly required. This will aid and accelerate the accessibility to a substantial 
collection of samples. Moreover, more global efforts need to be made in order to expand an 
online data-base from standardized data reports of the available pre-clinical STS models. This 
will facilitate the access to basic and translational cancer research as well and will optimize 
the exchange of information.  
   
 
 
Figure 1 – Potential of cancer-derived iPSCs in research and clinic. Cancer cells(benign & malignant) 
may be reprogrammed to induced pluripotent stem cells (iPSC) using the appropriate combination of 
reprogramming factors. These iPSCs can be differentiated along the developmental lineage they arose 
from, enabling scientists to study the different stages of tumorigenesis, identify early diagnostic 
biomarkers and perform drug screens. Cells derived from healthy tissues and, if available, benign 
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Soft tissue sarcomas (STS) are a rare and heterogenous group of cancers of predominantly 
mesenchymal origin. More than 50 subtypes are recognized mainly on basis of distinct 
morphological and pathological features. STS include local aggressive and malignant tumors 
arising in or from connective tissues such as synovial tissue, fat, muscle, peripheral nerves and 
fibrous or related tissues. Together the STS comprise about 1-2% of all adult malignancies and 
about 10% of all childhood malignancies. 
 
Treatment modalities of STS are surgery, radiotherapy and chemotherapy. Systemic 
chemotherapy is usually offered to patients with advanced, not amendable for curative local 
treatments and metastasized disease and is usually based on doxorubicin or ifosfamide in 
combination with docetaxel or gemcitabine. Prognosis varies and depends on histological 
subtype, tumor size, tumor grade and location. Despite the recent introduction of novel 
systemic treatments with drugs like pazopanib and trabectedin the outcome for patients with 
advanced disease remains poor with a median overall survival of approximately 12 months 
stressing the need for novel therapeutic approaches.  
 
The research described in this thesis concerns two STS subtypes, malignant peripheral nerve 
sheath tumors (MPNST) and gastrointestinal stromal tumors (GIST). The overall aim was to 
gain a better understanding of the biology of these tumors in order to explain their clinical 
behaviour and ultimately to improve treatment of these malignancies. In this context, special 
emphasis was given to a specific class of small non-coding RNAs i.e. microRNAs (miRNAs). 
These miRNAs capable of regulating gene expression, are commonly found dysregulated in 
cancer and fulfil essential roles in carcinogenic processes. Functional characterization of 
aberrantly expressed miRNAs in cancer may reveal interesting biology. Further, miRNAs can 
be exploited as diagnostic, prognostic or predictive biomarker and may have therapeutic 
potential.  
 
MPNST are highly aggressive cancers that occur spontaneously or arise from benign plexiform 
neurofibromas in the context of neurofibromatosis type 1 (NF1) with the latter process of 
malignant transformation, via an intermediary atypical neurofibroma, poorly understood. 
MPNST are prone to metastasize, have high local recurrence rates and are relatively resistant 
to therapeutic intervention. Metastatic MPNST almost always proves fatal. Novel, more 
effective treatment strategies are urgently needed. In Chapter 2 we examined known, 
topoisomerase IIα (TOP2A), and new drug targets, bromodomain containing protein 4 (BRD4) 
and zeste homolog 2 (EZH2). The expression of these genes was studied in plexiform and 
atypical neurofibromas, NF1-derived MPNST tissue samples and MPNST cell lines. We 
subsequently investigated whether expression levels were associated with sensitivity to 
specific pharmacological or genetic inhibitors of these genes. We showed that BRD4 transcript 
levels were not upregulated in MPNST compared to plexiform and atypical neurofibromas and 
that consequently MPNST cell lines were relatively insensitive to the bromodomain inhibitor 
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JQ1. Although EZH2 levels were consistently found upregulated in MPNST, genetic 
knockdown of EZH2 did not interfere with cellular proliferation and cell viability.  It was 
verified that TOP2A is overexpressed in MPNST samples and that a relative high expression 
of TOP2A in MPNST cell lines correlates to sensitivity to doxorubicin. It was concluded that 
therapeutic effects of targeting of BRD4, EZH2 and TOP2A, individually, may be limited. 
Chapter 3 focussed on the biology of MPNST particularly the involvement of miRNAs in 
cancer-related processes. A unique set of paired plexiform neurofibroma – MPNST samples, 
with each pair of tumors derived from the same patient, was used in miRNA expression 
profiling studies. Ninety miRNAs were found differentially expressed between MPNST and 
plexiform neurofibromas. Three downregulated (let-7b-5p; miR-145-5p and miR-143-3p) and 
two upregulated (miR-135b-5p and miR-889-3p) miRNAs in MPNST were selected for further 
validation and functional characterization in additional neurofibroma and MPNST samples and 
cell lines. Using in vitro experiments in which miRNA levels were transiently modulated it 
was established that the selected miRNAs generally did not interfere with cellular proliferation 
of MPNST cells. However, some miRNAs did affect the migratory and invasive capabilities, 
surrogates for metastasis, and Wnt signaling activity of MPNST cells but the effects differed 
depending on the cell line used. It was concluded that dysregulated miRNAs fulfil key roles in 
MPNST development and progression although in a cell context dependent fashion. 
 
The next two chapters deal with GIST. These tumors are found along the gastrointestinal tract 
and are believed to originate from the interstitial cells of Cajal, pacemaker cells responsible 
for the peristaltic movement. At a molecular level the majority of these tumors are 
characterized by mutually exclusive activating mutations in the tyrosine kinase receptors KIT 
and PDGFRA that drive the pathogenesis. The tyrosine kinase inhibitor imatinib plays a central 
role in the treatment of both localized and advanced GIST. Unfortunately, most patients 
eventually become resistant this drug and present with progressive disease. In Chapter 4 GIST 
was briefly introduced including its current treatment and the clinical needs regarding its 
management. In addition, different relevant classes of non-coding RNAs were presented. Next, 
the current literature on non-coding RNAs, with an emphasis on miRNAs, that are expressed 
in GIST and can be linked to distinct clinicopathological features like risk classification, 
imatinib resistance, metastasis, was reviewed. The need for and potential clinical use of non-
coding RNAs as biomarkers was critically evaluated. Finally, certain non-coding RNAs whose 
expression was deregulated in GIST and that played key roles in GIST biology were discussed 
in the light of their therapeutic potential. Chapter 5 addressed the phenomenon of imatinib-
resistance as observed in GIST. Our analyses highlighted miRNAs and mRNAs that were 
differentially expressed in imatinib-resistant GISTs compared to imatinib-naïve GISTs. At 
least thirty-five miRNAs and 352 mRNAs were identified in this manner and used as input for 
further pathway and network analyses that highlighted cell cycle related genes/gene networks 
in imatinib-resistant GIST. Some overexpressed proteins e.g. AURKA, AURKB and FOXM1 
in the resistant setting were considered amenable for inhibition by small molecules and three 
miRNAs, miR-92a-3p, miR-99a-5p and miR-101-3p were indicated as potential effectors of 
imatinib resistance. We concluded that further experimental in vitro and in vivo studies are 





Weke delen tumoren (sarcomen) vormen een zeldzame en heterogene groep kankers van 
mesenchymale origine. Op basis van morfologische en pathologische kenmerken worden meer 
dan 50 verschillende subtypen onderscheiden. De groep sarcomen bevat locaal agressieve en 
maligne tumoren die onstaan in of uit bindweefsel zoals synoviaal weefsel, vet, spier, perifere 
zenuwen en fibreus of gerelateerde weefsel. Samen omvatten de weke delen tumoren ongeveer 
1 a 2% van alle maligniteiten bij volwassenen en circa 10% van de maligniteiten die bij 
kinderen voorkomen. 
 
Belangrijk voor de behandeling van sarcomen zijn chirurgie, radiotherapie en chemotherapie. 
Systemische chemotherapie wordt gewoonlijk gegeven aan patiënten met gevorderde of 
gemetastatseerde ziekte die niet meer in aanmerking komen voor een locaal curatieve 
behandeling.  De chemotherapie is veelal gebaseerd op de middelen doxorubicine of 
ifosfamide in combinatie met docetaxel of gemcitabine. De prognose voor de patiënt varieert 
en is afhankelijk van het precieze sarcoom subtype, de tumor grootte, tumor gradering en de 
locatie van de tumor. Ondanks de recente introductie van nieuwe antikanker middelen, zoals 
pazopanib en trabectedine, blijft de uitkomst voor patiënten met gevorderde ziekte slecht met 
een mediane overleving van ongeveer 12 maanden. Dit benadrukt de noodzaak van de 
ontwikkeling van nieuwe therapeutische strategieën. 
 
Het onderzoek beschreven in dit proefschrift richt zich op twee verschillende typen sarcomen, 
kwaadaardige perifere zenuwschede tumoren (MPNST) en gastrointestinale stromale tumoren 
(GIST). Het doel was om een beter begrip te krijgen van de biologie van deze tumoren om zo 
hun klinische gedrag te kunnen verklaren en uiteindelijk te komen tot een betere behandeling 
van deze kankers. Speciale aandacht ging uit naar een specifieke klasse niet-coderende RNAs, 
de microRNAs (miRNAs). miRNAs zijn in staat genexpressie te reguleren, komen in kankers 
verstoord tot expressie en kunnen een essentiële rol vervullen in kankerontwikkeling en 
progressie. De functionele karakterisering van microRNAs in kanker kan interessante biologie 
onthullen. Verder kunnen miRNAs worden gebruikt als diagnostische, prognostische of 
predictieve biomarker en hebben ze mogelijk therapeutisch potentieel. 
 
MPNST zijn agressieve tumoren die spontaan kunnen ontstaan of uit benigne plexiforme 
neurofibromen in neurofibromatose type 1 (NF1) patiënten. Het proces dat ten grondslag ligt 
aan deze maligne transitie, dat verloopt via intermediaire atypische neurofibromen, wordt niet 
goed begrepen. MPNST metastaseert en recidiveert makkelijk en is relatief ongevoelig voor 
chemotherapie. Gemetastaseerde MPNST zijn bijna altijd dodelijk. Nieuwe en effectievere 
behandel mogelijkheden zijn nodig. In Hoofdstuk 2 onderzochten we bekende en nieuwe 
therapie aangrijpingspunten zoals  topoisomerase II alpha (TOP2A), het  bromodomein 
bevattend eiwit 4 (BRD4) en zeste homoloog 2 (EZH2). De expressie van deze genen werd 
bestudeerd in plexiform- en atypisch neurofibroom, NF1- gerelateerde MPNST en MPNST 
cellijnen. Vervolgens werd bepaald of de expressie geassocieerd was met gevoeligheid voor 
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specifieke farmacologische of genetische remmers. Aangetoond werd dat BRD4 mRNA 
niveaus niet verhoogd waren in MPNST in vergelijking tot plexiforme- en atypische 
neurofibromen en dat MPNST cellijnen relatief ongevoelig waren voor de bromodomein 
remmer JQ1. Hoewel EZH2 mRNA niveaus consequent verhoogd waren in MPNST, 
interfereerde een verlaging van EZH2 eiwit niet met cel proliferatie en cel viabiliteit. Het werd 
geverifieerd dat TOP2A verhoogd tot expressie komt in MPNST en dat een relatief hoog 
TOP2A niveau in cellijnen correleert met een gevoeligheid voor doxorubicine. Uit deze studie 
werd geconcludeerd dat het therapeutische effect van individuele BRD4, EZH2 en TOP2A 
remming gering is. Hoofdstuk 3 richtte zich op de biologie van MPNST, in het bijzonder de 
betrokkenheid van miRNAs bij kanker-gerelateerde processen. Hiertoe werd het miRNA 
expressie profiel bepaald van een unieke set gepaarde plexiform neurofibroom - MPNST 
monsters, waarbij elk afzonderlijk paar tumoren afkomstig is van een zelfde NF1 patiënt. 
Negentig miRNAs kwamen differentieel tot expressie in MPNST en plexiforme 
neurofibromen. Drie miRNAs (let-7b-5p; miR-145-5p en miR-143-3p) die verlaagd tot 
expressie kwamen in MPNST en twee miRNAs (miR-135b-5p en miR-889-3p)  die verhoogd 
waren, werden geselecteerd voor verdere validatie en functionele karakterisering in 
aanvullende neurofibromen en MPNST weefsels en cellijnen. Gebruik makend van in vitro 
experimenten waarin miRNA niveaus tijdelijk werden verhoogd of verlaagd werd vastgesteld 
dat de geselecteerde miRNAs de cel proliferatie van MPNST cellen niet beïnvloeden. 
Daarentegen, hadden sommige miRNAs wel een effect op de migratie en invasie van MPNST 
cellen, beide surrogaat processen voor metastasering, echter de effecten waren niet in alle 
cellijnen hetzelfde. Ook werd de activiteit van het Wnt signalerings pad door miRNAs 
beïnvloed. Geconcludeerd werd dat tenminste een aantal miRNAs een belangrijke rol spelen 
bij MPNST ontwikkeling en progressie maar op een cel context afhankelijke wijze. 
 
De volgende twee hoofdstukken behandelen ons onderzoek van GIST. Deze tumoren worden 
gevonden langs het gastrointestinale stelsel en worden verondersteld te ontstaan uit de 
interstitiële cellen van Cajal; pacemaker cellen verantwoordelijk voor de peristaltiek.  Op 
moleculair niveau wordt de meerderheid van deze tumoren gekarakteriseerd door activerende 
mutaties in de tyrosine kinase receptoren KIT of PDGFRA die ten grondslag liggen aan de 
pathogenese. De tyrosine kinase remmer imatinib vervult een centrale rol in de behandeling 
van zowel locaal als gevorderde GIST. Deze meeste patiënten ontwikkelen na verloop van tijd 
resistentie voor imatinib dat leidt tot tumor progressie. GIST werd bondig geïntroduceerd in 
Hoofdstuk 4 waarin ook de huidige behandeling van deze tumoren en de klinische behoeften 
voor verdere optimalisatie van de behandeling werden meegenomen. Verder werden 
verschillende, relevante klassen niet-coderende RNAs besproken. Vervolgens werd de 
wetenschappelijke literatuur handelend over niet-coderende RNAs, met de nadruk op 
miRNAs, in GIST systematisch doorgenomen met daarbij vooral aandacht voor niet-
coderende RNAs die zijn geassocieerd met klinische- en pathologische kenmerken zoals risico 
evaluatie, imatinib resistentie en metastasering. De behoefte aan, en potentieel gebruik van, 
niet-coderende RNAs als biomarker in de klinische praktijk werden kritisch bediscussieerd. 
Ten slotte werd het therapeutische potentieel  van niet-coderende RNAs beschouwd met name 
van RNAs die aberrant tot expressie komen en die een sleutelrol vervullen in de GIST biologie. 
Het fenomeen imatinib resistentie zoals dat wordt waargenomen in GIST werd in Hoofdstuk 
5 onderzocht. Onze analyses identificeerden miRNAs en mRNAs die differentieel tot expressie 
komen in imatinib-naïve  en imatinib-resistentie GIST. Tenminste 35 miRNAs en 352 mRNAs 
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werden gedetecteerd en gebruikt als input voor biochemische pad en netwerk analyses. In 
imatinib-resistente GIST werden celcyclus genen/gen netwerken gedetecteerd. Sommige van 
de verhoogd tot expressie komende genen in imatinib-resistente GIST zoals AURKA, AURKB 
en FOXM1 kunnen mogelijk worden geremd met specifieke doelgerichte medicijnen. Verder 
werd een drietal miRNAs, miR-92a-3p, miR-99a-5p en miR-101-3p, in verband gebracht met 
imatinib-resistentie. Geconcludeerd werd dat verdere experimentele in vitro en in vivo studies 
noodzakelijk zijn om de bevindingen verder te valideren en te onderbouwen 
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